[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"SA3, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":387},{"warningLetters":4,"total":386},[5,32,53,74,94,113,131,150,166,183,203,229,245,264,280,298,312,331,352,369],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},1087,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-01-21T14:20:00Z\">01\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-15T05:00:00Z\">01\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsanofi-690604-01152025\">Sanofi\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-22\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Paul Hudson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sanofi\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>54, Rue La Boétie\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>75008\u003C\u002Fspan> \u003Cspan>Paris\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>France\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-22\u003C\u002Fp>\u003Cp>January 15, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>AMENDED\u003C\u002Fstrong>\u003Cbr>(This letter replaces Warning Letter No. 320-25-22 dated December 16, 2024.)\u003C\u002Fp>\u003Cp>Dear Mr. Hudson:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Genzyme Corporation (a Sanofi subsidiary), FEI 1220423, at 8, 31, 45, 49, 51, 55, 68, 74, 76, 80 New York Ave., Framingham, MA, from June 12 to July 9, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your July 29, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to investigate all critical deviations.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA documented that approximately 20 percent of bioreactor runs attempted between January 2022 and July 2024 were rejected for contamination or other quality failures. This rate is excessive and calls into question the state of control of your process. You failed to conduct adequate investigations into critical deviations, including multiple microbiological contamination events recorded in this timeframe. For example:\u003C\u002Fp>\u003Cp>A. Two lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and three lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> were out-of-specification (OOS) for appearance due to the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles and were not adequately investigated.\u003C\u002Fp>\u003Cp>B. Three in-process high-pressure events associated with product leakage during the transfer of bulk \u003Cstrong>(b)(4)\u003C\u002Fstrong> through a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> L shipping bags were not adequately investigated.\u003C\u002Fp>\u003Cp>Your investigations failed to identify all potential contributing causes, did not consider the conclusions of an engineering study that contradicted your assigned root cause for the OOS appearance events, and did not document all investigational activities, including the collection of at least one sample found in a storage room by FDA investigators.\u003C\u002Fp>\u003Cp>In your response, you reference numerous corrective actions and preventive actions (CAPAs) initiated to address the inadequate investigations into the microbiological contamination and the in-process high-pressure events including:\u003C\u002Fp>\u003Cp>• “… additional quality oversight of significant deviations…,”\u003Cbr>• implementation of “… an investigation job aid” for \u003Cstrong>(b)(4)\u003C\u002Fstrong> technology items that help determine product impact,\u003Cbr>• and revising your procedure governing appearance testing of APIs to ensure the observation of particles will result in an investigation that includes particle characterization.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide the completed investigations alluded to in your response, identify the root cause(s), justify each CAPA, or explain how the effectiveness of the CAPA will be determined. You also did not address the impact of excessive \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles in your drug substances potentially reducing the ability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to successfully remove objectional microbiological contamination.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• An update on your investigation into reducing particle load in your process. Include in this update both an updated control and removal strategy, including an analysis of load, \u003Cstrong>(b)(4)\u003C\u002Fstrong> capacity, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and parameters to monitor to ensure \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to remove microorganisms are not adversely affected by \u003Cstrong>(b)(4)\u003C\u002Fstrong> from particulates.\u003Cbr>• A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003Cbr>• A retrospective, independent review of all investigations into unexplained discrepancies or the failure of a batch or any of its components to meet any of its specifications for U.S. products, irrespective of whether the batch was ultimately distributed in the U.S. market, and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each investigation: o Determine whether each investigation was thorough, described all investigational activities, including sampling and analysis of samples, identified root cause(s), identified scientifically justified CAPA and appropriate means of determining CAPA effectiveness.\u003Cbr>&nbsp; o Determine whether the scientific justification and evidence relating to an invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>&nbsp; o For investigations that conclusively establish root cause, provide rationale and ensure that all other methods, procedures, processes, and materials vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>&nbsp; o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You repeatedly deviated from your validated manufacturing process for the production of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example:\u003C\u002Fp>\u003Cp>A. You performed \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bioreactor runs while the manufacturing process was validated with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You identified the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process as increasing the risk of microbiological contamination events in an investigation into a March 2024 in-process contamination event.\u003C\u002Fp>\u003Cp>B. Your manufacturing personnel were observed to use a written work instruction (Pre-Job Briefing) describing itself as “… not a GMP document\u002Fprocess…” to deviate from your validated manufacturing procedure by replacing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong> L shipping bag to control the frequency of high-pressure and in-process leaking events. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process described in the electronic batch record used by manufacturing personnel was validated using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to process the transfilling of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> L shipping bags used in a batch.\u003C\u002Fp>\u003Cp>In your response, you commit to executing a protocol intended to identify additional CAPA to increase control of upstream processing and thereby reduce the incidence of microbiological contamination events. In addition, you commit to prohibiting the practice of replacing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong> L shipping bag during the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also state the Pre-Job Briefing document was used incorrectly to implement the change to the validated manufacturing process and commit to identify and correct any other manufacturing instructions that rely on a Pre-Job Briefing document to deviate from the validated manufacturing process.\u003C\u002Fp>\u003Cp>Your response is inadequate. There is no indication you initiated an investigation into your deviating from the validated manufacturing process by replacing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling bags on multiple occasions. In addition, there is no retrospective review of batch records for batches within expiry, to identify any other process deviations performed without the appropriate corresponding documentation including risk assessment(s). You did not provide your rationale for ending the practice of replacing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> L shipping bag during the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Furthermore, you did not identify an alternative control strategy to address the high-pressure events that resulted in the in-process product leakage events. You also did not investigate or describe your CAPA to address your QU’s roles in these deviations from validated manufacturing processes.\u003C\u002Fp>\u003Cp>When significant variability is observed in a drug manufacturing process or in its input materials, it is essential for executive management to support and implement effective actions to promptly address the source(s) of the variation and ensure a continued state of control.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• An assessment of each drug production process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003Cbr>• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003Cbr>• Timelines for completed further process performance qualification studies on remediated processes for marketed drug products for which a state of control has not been adequately\u002Ffully established.\u003Cbr>• Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003Cbr>• A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to have equipment of the appropriate design and suitability for their intended use for the manufacture of APIs.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm used equipment unsuitable for its intended use in microbiologically controlled manufacturing environments. For example:\u003C\u002Fp>\u003Cp>A. Mobile carts used in the setup of \u003Cstrong>(b)(4)\u003C\u002Fstrong> units required operators to get down to the floor and manually lock and unlock the cart brakes despite previously determining equipment proximity to the floor as a contributing root cause in microbiological contamination events.\u003C\u002Fp>\u003Cp>B. \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to establish temporary sterile boundaries for tubing continue to be used despite being identified in a June 2023 microbial contamination event investigation as possessing a “design flaw” that may allow microbial ingress.\u003C\u002Fp>\u003Cp>In your response, you commit to removing all brakes from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> carts, assessing potential design improvements to the carts, and you note supplemental contamination control training to manufacturing personnel. You explain the previous documented description of a design flaw in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was incorrect, and the problem is a “design limitation” that requires specific instruction to fully mitigate the risk of microbiological contamination. You also commit to verification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> usage by a second operator.\u003C\u002Fp>\u003Cp>Your response is inadequate. You disregarded your previous conclusion that equipment and personnel proximity to the floor is a contributing root cause in microbiological contamination events and state the design of the mobile carts is “… fit for purpose when used per the SOP and in a manner consistent with manufacturing training.” You do not commit to reassess manufacturing equipment to ensure it is of appropriate design to minimize the risk of microbial contamination. You do not describe the \u003Cstrong>(b)(4)\u003C\u002Fstrong> “design limitation” or explain why this “design limitation” was not previously mitigated. You also do not discuss how the revised instructions for usage and verification will mitigate the risk associated with their use.\u003C\u002Fp>\u003Cp>In response to this letter provide, your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, ensuring suitability for use, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure of your quality unit to exercise its responsibility to ensure the API manufactured at your facility are in compliance with CGMP.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection documented approximately 84 open and past due deviation investigations existed as of June 21, 2024. For example:\u003C\u002Fp>\u003Cp>A. QE-000270 (187 days past due)\u003Cbr>B. QE-004069 (179 days past due)\u003Cbr>C. QE-004896 (129 days past due)\u003Cbr>D. QE-023790 (45 days past due)\u003C\u002Fp>\u003Cp>Multiple past due investigations also lacked procedurally required extensions to the due date.\u003C\u002Fp>\u003Cp>The procedure governing deviation handling requires non-significant deviations be closed within \u003Cstrong>(b)(4)\u003C\u002Fstrong> and significant deviations be closed within \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The procedure further requires a documented and approved request for extension in the event a deviation investigation cannot be closed within the specified timeframe.\u003C\u002Fp>\u003Cp>In your response, you identify four contributing root causes: excessive personnel attrition of trained investigators, process knowledge gaps amongst newer investigators, prioritization of investigations associated with lots pending release, and inconsistent communication of “deviation performance metrics.”\u003C\u002Fp>\u003Cp>Your response is inadequate. Although you identified CAPA, for each contributing root cause, you did not provide sufficient detail for their implementation. You commit to adding resources to your “Compliance Engineer and QA team to sustain the deviation quality system…” and assess this action “… against adherence to performance metrics and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> planning exercises for resource allocation.” You also commit to reassigning existing personnel and to bring in subject matter experts to assist with addressing the investigation backlog but do not explain how this will impact other operations, how these personnel will be trained to conduct specific aspects of the investigations, and how their performance will be monitored and assessed.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources, including adequate training, to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>o Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to ensure all production deviations are reported and evaluated, and that critical deviations are investigated, and the conclusions are recorded.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Multiple production deviations went unaddressed until our investigators informed facility personnel of the issues. For example:\u003C\u002Fp>\u003Cp>A. An \u003Cstrong>(b)(4)\u003C\u002Fstrong> line used for aseptic processing was observed to be touching the floor during \u003Cstrong>(b)(4)\u003C\u002Fstrong> setup activities. The batch record specifically includes an instruction for personnel to ensure production lines do not contact the floor.\u003Cbr>B. An operator was observed to touch their gown and hairnet with their hands and then handle sterile manufacturing equipment without sanitizing their hands.\u003Cbr>C. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> located between the \u003Cstrong>(b)(4)\u003C\u002Fstrong> L \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a \u003Cstrong>(b)(4)\u003C\u002Fstrong> L shipping bag was observed to be oriented \u003Cstrong>(b)(4)\u003C\u002Fstrong> during processing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The batch record specifically instructs personnel to orient the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you commit to conducting additional training for all facility personnel and to revise your \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination control training to include additional instructions on when to use \u003Cstrong>(b)(4)\u003C\u002Fstrong> and when gowning changes are appropriate. You also commit to making procedural changes associated with equipment management and using additional resources for operational coaching and oversight.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide your investigation(s) into the objectionable behaviors, assess your training program, or assess your oversight of setup and manufacturing operations.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• Your investigation(s) into the objectionable behaviors.\u003Cbr>• Your revision(s) to personnel training and written procedures that instruct personnel on proper aseptic practices including situations requiring sanitization of gloves.\u003Cbr>• An assessment of training program effectiveness for all training given to personnel performing activities in, and in support of, production activities. Your assessment should include identification of specific CAPA, date(s) of implementation, and the means of determining CAPA effectiveness.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter indicate that your QU is not able to fully exercise its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any deviations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1220423 and ATTN: Jason F. Chancey.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-22\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Paul Hudson\n\nRecipient Title\n\nChief Executive Officer\n\nSanofi\n\n54, Rue La Boétie\n\n75008 Paris\n\nFrance\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-22\nJanuary 15, 2025\nAMENDED\n(This letter replaces Warning Letter No. 320-25-22 dated December 16, 2024.)\nDear Mr. Hudson:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Genzyme Corporation (a Sanofi subsidiary), FEI 1220423, at 8, 31, 45, 49, 51, 55, 68, 74, 76, 80 New York Ave., Framingham, MA, from June 12 to July 9, 2024.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your July 29, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific deviations including, but not limited to, the following.\n1. Failure to investigate all critical deviations.\nFDA documented that approximately 20 percent of bioreactor runs attempted between January 2022 and July 2024 were rejected for contamination or other quality failures. This rate is excessive and calls into question the state of control of your process. You failed to conduct adequate investigations into critical deviations, including multiple microbiological contamination events recorded in this timeframe. For example:\nA. Two lots of (b)(4) and three lots of (b)(4) were out-of-specification (OOS) for appearance due to the presence of (b)(4) particles and were not adequately investigated.\nB. Three in-process high-pressure events associated with product leakage during the transfer of bulk (b)(4) through a (b)(4) to (b)(4) L shipping bags were not adequately investigated.\nYour investigations failed to identify all potential contributing causes, did not consider the conclusions of an engineering study that contradicted your assigned root cause for the OOS appearance events, and did not document all investigational activities, including the collection of at least one sample found in a storage room by FDA investigators.\nIn your response, you reference numerous corrective actions and preventive actions (CAPAs) initiated to address the inadequate investigations into the microbiological contamination and the in-process high-pressure events including:\n• “… additional quality oversight of significant deviations…,”\n• implementation of “… an investigation job aid” for (b)(4) technology items that help determine product impact,\n• and revising your procedure governing appearance testing of APIs to ensure the observation of particles will result in an investigation that includes particle characterization.\nYour response is inadequate. You did not provide the completed investigations alluded to in your response, identify the root cause(s), justify each CAPA, or explain how the effectiveness of the CAPA will be determined. You also did not address the impact of excessive (b)(4) particles in your drug substances potentially reducing the ability of (b)(4) to successfully remove objectional microbiological contamination.\nIn response to this letter, provide:\n• An update on your investigation into reducing particle load in your process. Include in this update both an updated control and removal strategy, including an analysis of load, (b)(4) capacity, (b)(4), and parameters to monitor to ensure (b)(4) used to remove microorganisms are not adversely affected by (b)(4) from particulates.\n• A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n• A retrospective, independent review of all investigations into unexplained discrepancies or the failure of a batch or any of its components to meet any of its specifications for U.S. products, irrespective of whether the batch was ultimately distributed in the U.S. market, and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each investigation: o Determine whether each investigation was thorough, described all investigational activities, including sampling and analysis of samples, identified root cause(s), identified scientifically justified CAPA and appropriate means of determining CAPA effectiveness.\no Determine whether the scientific justification and evidence relating to an invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish root cause, provide rationale and ensure that all other methods, procedures, processes, and materials vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n2. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes.\nYou repeatedly deviated from your validated manufacturing process for the production of (b)(4). For example:\nA. You performed (b)(4) of the (b)(4) during (b)(4) of the (b)(4) bioreactor runs while the manufacturing process was validated with (b)(4). You identified the (b)(4) process as increasing the risk of microbiological contamination events in an investigation into a March 2024 in-process contamination event.\nB. Your manufacturing personnel were observed to use a written work instruction (Pre-Job Briefing) describing itself as “… not a GMP document\u002Fprocess…” to deviate from your validated manufacturing procedure by replacing the (b)(4) with (b)(4) L shipping bag to control the frequency of high-pressure and in-process leaking events. The (b)(4) manufacturing process described in the electronic batch record used by manufacturing personnel was validated using a (b)(4) to process the transfilling of all (b)(4) L shipping bags used in a batch.\nIn your response, you commit to executing a protocol intended to identify additional CAPA to increase control of upstream processing and thereby reduce the incidence of microbiological contamination events. In addition, you commit to prohibiting the practice of replacing the (b)(4) with (b)(4) L shipping bag during the manufacture of (b)(4). You also state the Pre-Job Briefing document was used incorrectly to implement the change to the validated manufacturing process and commit to identify and correct any other manufacturing instructions that rely on a Pre-Job Briefing document to deviate from the validated manufacturing process.\nYour response is inadequate. There is no indication you initiated an investigation into your deviating from the validated manufacturing process by replacing the (b)(4) filling bags on multiple occasions. In addition, there is no retrospective review of batch records for batches within expiry, to identify any other process deviations performed without the appropriate corresponding documentation including risk assessment(s). You did not provide your rationale for ending the practice of replacing the (b)(4) for (b)(4) L shipping bag during the manufacture of (b)(4). Furthermore, you did not identify an alternative control strategy to address the high-pressure events that resulted in the in-process product leakage events. You also did not investigate or describe your CAPA to address your QU’s roles in these deviations from validated manufacturing processes.\nWhen significant variability is observed in a drug manufacturing process or in its input materials, it is essential for executive management to support and implement effective actions to promptly address the source(s) of the variation and ensure a continued state of control.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\n• An assessment of each drug production process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n• Timelines for completed further process performance qualification studies on remediated processes for marketed drug products for which a state of control has not been adequately\u002Ffully established.\n• Process performance protocol(s), and written procedures for qualification of equipment and facilities.\n• A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n3. Failure to have equipment of the appropriate design and suitability for their intended use for the manufacture of APIs.\nYour firm used equipment unsuitable for its intended use in microbiologically controlled manufacturing environments. For example:\nA. Mobile carts used in the setup of (b)(4) units required operators to get down to the floor and manually lock and unlock the cart brakes despite previously determining equipment proximity to the floor as a contributing root cause in microbiological contamination events.\nB. (b)(4) used to establish temporary sterile boundaries for tubing continue to be used despite being identified in a June 2023 microbial contamination event investigation as possessing a “design flaw” that may allow microbial ingress.\nIn your response, you commit to removing all brakes from the (b)(4) carts, assessing potential design improvements to the carts, and you note supplemental contamination control training to manufacturing personnel. You explain the previous documented description of a design flaw in the (b)(4) was incorrect, and the problem is a “design limitation” that requires specific instruction to fully mitigate the risk of microbiological contamination. You also commit to verification of the (b)(4) usage by a second operator.\nYour response is inadequate. You disregarded your previous conclusion that equipment and personnel proximity to the floor is a contributing root cause in microbiological contamination events and state the design of the mobile carts is “… fit for purpose when used per the SOP and in a manner consistent with manufacturing training.” You do not commit to reassess manufacturing equipment to ensure it is of appropriate design to minimize the risk of microbial contamination. You do not describe the (b)(4) “design limitation” or explain why this “design limitation” was not previously mitigated. You also do not discuss how the revised instructions for usage and verification will mitigate the risk associated with their use.\nIn response to this letter provide, your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, ensuring suitability for use, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n4. Failure of your quality unit to exercise its responsibility to ensure the API manufactured at your facility are in compliance with CGMP.\nOur inspection documented approximately 84 open and past due deviation investigations existed as of June 21, 2024. For example:\nA. QE-000270 (187 days past due)\nB. QE-004069 (179 days past due)\nC. QE-004896 (129 days past due)\nD. QE-023790 (45 days past due)\nMultiple past due investigations also lacked procedurally required extensions to the due date.\nThe procedure governing deviation handling requires non-significant deviations be closed within (b)(4) and significant deviations be closed within (b)(4). The procedure further requires a documented and approved request for extension in the event a deviation investigation cannot be closed within the specified timeframe.\nIn your response, you identify four contributing root causes: excessive personnel attrition of trained investigators, process knowledge gaps amongst newer investigators, prioritization of investigations associated with lots pending release, and inconsistent communication of “deviation performance metrics.”\nYour response is inadequate. Although you identified CAPA, for each contributing root cause, you did not provide sufficient detail for their implementation. You commit to adding resources to your “Compliance Engineer and QA team to sustain the deviation quality system…” and assess this action “… against adherence to performance metrics and the (b)(4) planning exercises for resource allocation.” You also commit to reassigning existing personnel and to bring in subject matter experts to assist with addressing the investigation backlog but do not explain how this will impact other operations, how these personnel will be trained to conduct specific aspects of the investigations, and how their performance will be monitored and assessed.\nIn response to this letter, provide:\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources, including adequate training, to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\no Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n5. Failure to ensure all production deviations are reported and evaluated, and that critical deviations are investigated, and the conclusions are recorded.\nMultiple production deviations went unaddressed until our investigators informed facility personnel of the issues. For example:\nA. An (b)(4) line used for aseptic processing was observed to be touching the floor during (b)(4) setup activities. The batch record specifically includes an instruction for personnel to ensure production lines do not contact the floor.\nB. An operator was observed to touch their gown and hairnet with their hands and then handle sterile manufacturing equipment without sanitizing their hands.\nC. The (b)(4) located between the (b)(4) L (b)(4) and a (b)(4) L shipping bag was observed to be oriented (b)(4) during processing of (b)(4) lot (b)(4). The batch record specifically instructs personnel to orient the (b)(4).\nIn your response, you commit to conducting additional training for all facility personnel and to revise your (b)(4) contamination control training to include additional instructions on when to use (b)(4) and when gowning changes are appropriate. You also commit to making procedural changes associated with equipment management and using additional resources for operational coaching and oversight.\nYour response is inadequate. You do not provide your investigation(s) into the objectionable behaviors, assess your training program, or assess your oversight of setup and manufacturing operations.\nIn response to this letter, provide:\n• Your investigation(s) into the objectionable behaviors.\n• Your revision(s) to personnel training and written procedures that instruct personnel on proper aseptic practices including situations requiring sanitization of gloves.\n• An assessment of training program effectiveness for all training given to personnel performing activities in, and in support of, production activities. Your assessment should include identification of specific CAPA, date(s) of implementation, and the means of determining CAPA effectiveness.\nQuality Unit Authority\nSignificant findings in this letter indicate that your QU is not able to fully exercise its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any deviations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1220423 and ATTN: Jason F. Chancey.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Sanofi","sanofi-690604-01152025","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsanofi-690604-01152025","2026-10-26T08:09:53.77923+00:00","Warning Letter","Issued","2025-01-21","690604","Drugs","Mr. Paul Hudson","2026-08-19T17:04:17.181+00:00","Via Email","320-25-22","2025-01-15",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":47,"medical_device_id":19,"response_letter_date":19},3096,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2021-10-07T13:00:00Z\">10\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-07T04:00:00Z\">10\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsadboy-llc-618811-10072021\">Sadboy LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Edward Myers and Robert Wiley\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Sadboy LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1811 Roseberry Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Philadelphia\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19145\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@phillyvapesociety.com\"> sales@phillyvapesociety.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Edward Myers and Robert Wiley:&nbsp;\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fphillyvapesociety.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. &nbsp;Certain tobacco products, including e-liquid products are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. &nbsp;Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. &nbsp;These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. &nbsp;See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>N\u003Cstrong>ew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fphillyvapesociety.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Sadboy E-liquid Pumpkin Cookie 100ml and Sadboy E-liquid Key Lime Cookie 100ml.&nbsp;\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. &nbsp;In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 40 products listed with FDA. &nbsp;FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0003534 on September 9, 2020. However, FDA issued a negative action for PMTA STN PM0003534 in the form of a Marketing Denial Order determination on September 3, 2021, which covers 53 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0003534 that resulted in a Marketing Denial Order determination, are adulterated and misbranded.&nbsp;\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. &nbsp;Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>. &nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. &nbsp;Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. &nbsp;However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. &nbsp;Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. &nbsp;You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101642, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:&nbsp;\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov. &nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nVIA UPS and Electronic Mail&nbsp;\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Liquid Filling Solutions, LLC\u003Cbr>\n900 Madison Avenue\u003Cbr>\nEagleville, PA 19403\u003C\u002Fp>\n\n\u003Cp>Liquid Filling Solutions, LLC\u003Cbr>\n761 5th Avenue\u003Cbr>\nKing of Prussia, PA 19406\u003C\u002Fp>\n\n\u003Cp>Philly Vape Society, LLC &nbsp;\u003Cbr>\nsales@phillyvapsociety.com&nbsp;\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com &nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nEdward Myers and Robert Wiley\n\nSadboy LLC\n\n1811 Roseberry Street\n\nPhiladelphia, PA 19145\n\nUnited States\n\n(b)(6)\n\nsales@phillyvapesociety.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Edward Myers and Robert Wiley:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fphillyvapesociety.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fphillyvapesociety.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Sadboy E-liquid Pumpkin Cookie 100ml and Sadboy E-liquid Key Lime Cookie 100ml.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 40 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0003534 on September 9, 2020. However, FDA issued a negative action for PMTA STN PM0003534 in the form of a Marketing Denial Order determination on September 3, 2021, which covers 53 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0003534 that resulted in a Marketing Denial Order determination, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101642, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nLiquid Filling Solutions, LLC\n\n900 Madison Avenue\n\nEagleville, PA 19403\n\nLiquid Filling Solutions, LLC\n\n761 5th Avenue\n\nKing of Prussia, PA 19406\n\nPhilly Vape Society, LLC\n\nsales@phillyvapsociety.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com","Sadboy LLC","sadboy-llc-618811-10072021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsadboy-llc-618811-10072021","2026-10-26T08:09:52.426264+00:00","2021-10-07","618811","Tobacco","Edward Myers and Robert Wiley","2026-08-20T02:34:08.562+00:00","VIA UPS and Electronic Mail",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":26,"closeout_date":19,"issuing_office":59,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},2976,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2021-12-14T14:20:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-29T05:00:00Z\">11\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsanitor-corporation-616232-11292021\">Sanitor Corporation\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL CONFIRMED DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jon B. Robinson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sanitor Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8400 W. Cerritos Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Stanton\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90680\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sanilex@hotmail.com\"> sanilex@hotmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mr. Robinson:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Sanitor Corporation, FEI 3005871025, at 8400 W. Cerritos Avenue, Stanton, California, from May 25, 2021, to June 3, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).&nbsp;\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures \u003Cstrong>(b)(4) \u003C\u002Fstrong>and\u003Cstrong>&nbsp;(b)(4)&nbsp;\u003C\u002Fstrong>drug products to bleach and\u002For lighten the skin. These products are unapproved new drugs in violation of section 505(a) of the Federal Food &amp; Cosmetic Act (FD&amp;C Act,) 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d). In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a misbranded drug under section 502(c) of the FD&amp;C Act, 21 U.S.C. 352(c). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong>) are not listed with FDA as required by section 510(j) of the FD&amp;C Act. Failure to properly list a drug product is prohibited and will render a drug misbranded under 21 U.S.C. 331(p), 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 24, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1.&nbsp;&nbsp; &nbsp;Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate investigations\u002FLack of process control\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You contract manufacture over-the-counter drug products including benzalkonium chloride-based hand sanitizer.\u003Ca id=\"footnoteref1_zkcowck\" href=\"#footnote1_zkcowck\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa> &nbsp;Multiple batches of hand sanitizer drug product failed microbial total plate count (TPC) testing with results of Too Numerous to Count (TNTC). Your quality unit (QU) failed to adequately investigate and identify the root cause for the microbial contamination in your hand sanitizer drug product. Instead of conducting a thorough investigation and implementing corrective action to prevent contamination, your QU:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Approved the addition of an antimicrobial preservative to batches that initially failed microbial TPC testing, and were then released for distribution by your customer; and\u003Cbr>\n•&nbsp;&nbsp; &nbsp;Approved the addition of an antimicrobial preservative to batches not yet tested for microbial TPC so that they would yield a passing result, and were released for distribution by your customer.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Additionally, stability samples of a batch of hand sanitizer drug products (previously released without the addition of the preservative) failed the three-month stability test interval for microbial TPC with a result of TNTC. You stated that you notified the customer and recommended a voluntary recall of the drug product. Your customer declined to do so and informed you that the lot was sold and consumed. No further actions were taken.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you have performed a management review with your consultant and determined that your procedures were “inadequately robust and\u002For detailed.” Your response is inadequate in part, because you did not provide a thorough investigation into the microbial failures. You also did not provide adequate details of your consultant’s review and remedial actions. Further, your QU did not exercise its duties and oversight to ensure that future investigations are thorough, including root cause determination and appropriate corrective action strategies.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003Cbr>\n•&nbsp;&nbsp; &nbsp;A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complete investigations into all batches with potential objectionable microbial contamination or an out-of-specification &nbsp;microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Approving shipment of drug products before adequate review\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your QU approved drug products for distribution without complete finished product testing. For example, your firm shipped hand sanitizer batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> to your customer on June 1, 2020. However, the analytical results were only available as of on June 3, 2020, and the microbiological results were received on June 8, 2020. Your QU approved the certificate of analysis on June 3, 2020, before receiving the microbiological test results and after the batch was shipped to your customer.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you would “transfer” unreleased finished products to your customers under a verbal agreement that the products would not be distributed into interstate commerce until the batch was approved and released by your QU. This practice is unacceptable and increases the risk that drug products that do not meet their quality attributes are distributed to consumers. Complete testing of each batch of drug product before release is required to determine if the drug products you manufacture meet appropriate specifications.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide an independent retrospective review of all hand sanitizer drug products you manufactured to ensure no failing products were distributed. If the review reveals substandard quality drug products were distributed, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate stability program&nbsp;\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your QU lacked adequate quality oversight over your stability program. For example, you failed to follow your \u003Cem>Package Compatibility Test Program\u003C\u002Fem> procedure, and place \u003Cstrong>(b)(4)\u003C\u002Fstrong> of each product on \u003Cstrong>(b)(4)\u003C\u002Fstrong> stability testing to represent the product and process for your hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that the formulation for your hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products is packaged into \u003Cstrong>(b)(4)\u003C\u002Fstrong> different products and that all such products were initially placed on stability. Further, you noted that because the formulation, the packaging size, and the material of construction is the same for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> products, you are using a bracketing design to conduct the \u003Cstrong>(b)(4)\u003C\u002Fstrong> stability testing. However, your response indicated different container closure system designs. Therefore, the bracketing design does not appear scientifically justified. Additionally, this change to add a bracketing approach to your stability program for these products was implemented without adequate change control.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>\no&nbsp;&nbsp; &nbsp;Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\no&nbsp;&nbsp; &nbsp;Stability-indicating methods\u003Cbr>\no&nbsp;&nbsp; &nbsp;An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\no&nbsp;&nbsp; &nbsp;Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A list of expiration dates, with associated justification, for all drug products (e.g., 3 years of real time stability data).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate quality oversight over documentation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>During the review of a batch record for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, our investigators noted that production activities were not recorded contemporaneously. For example, the batch record documented that one employee performed multiple manufacturing steps, such as measuring containers and bulk reconciliation on two separate dates, and a second employee documented the verification of the activities. However, the second employee (verifier) stated to our investigator that they were not at work when these steps were documented as being performed. Your QU oversight does not provide adequate assurance that manufacturing records are accurate, and that production was performed as documented.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge that good documentation practices were not followed. You also stated that you performed training of all personnel. Your response is inadequate. Your quality system has not adequately ensured the accuracy and integrity of the data to support the safety, effectiveness, and quality of the drugs you manufacture. Without accurate records, you cannot assure appropriate decisions regarding batch release, product stability, and other matters that are fundamental to the ongoing assurance of quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>The examples above demonstrate the fundamental failure of your QU to perform its roles and responsibilities, but not limited to, oversight over process control, investigation handling, batch review and disposition, and appropriate control of data.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:&nbsp;\u003Cbr>\no&nbsp;&nbsp; &nbsp;A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\no&nbsp;&nbsp; &nbsp;Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\no&nbsp;&nbsp; &nbsp;A complete and final review of each batch and its related information before the QU disposition decision\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. Also, describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>On September 20, 2021, FDA held a teleconference with you and your consultant. We recommended that you consider removing all of your firm’s hand sanitizer drug products within expiry that were manufactured under the conditions referenced in this letter. On September 21, 2021, you voluntary recalled certain batches of hand sanitizer drug products. On September 22, 2021, FDA notified the public of your lack of adequate controls to prevent microbial contamination at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.&nbsp;\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2.&nbsp;&nbsp; &nbsp;Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You released and distributed multiple reworked batches and newly reformulated batches of your hand sanitizer drug product, without demonstrating the antimicrobial effectiveness testing of the preservative added to the product formulation. Specifically, a batch of your hand sanitizer drug product failed microbial TPC during bulk stage release testing with a result of TNTC. You reworked this batch by adding an antimicrobial preservative. Your deviation report stated that preservative adds microbial stability while not affecting the benzalkonium assay.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you submitted a sample to your contract testing lab to perform antimicrobial effectiveness testing on your hand sanitizer drug product and the results provide evidence of the effectiveness of the addition of the preservative to the formulation.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide complete laboratory data from your contract laboratory. As per USP &lt;51&gt;, antimicrobial preservatives should not be used as a substitute for good manufacturing practices or solely to reduce the viable microbial population of a nonsterile drug product.&nbsp;\u003Cbr>\n&nbsp;\u003Cbr>\nIn your response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Appropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A timeline for performing appropriate process performance qualification for each of your marketed drug products.&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3.&nbsp;&nbsp; &nbsp;Your firm failed to exercise appropriate controls over computer or related systems to &nbsp; assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Fourier Transform Infrared (FTIR) Spectroscopy computerized system did not have appropriate controls in place to prevent deletion of raw laboratory data. Specifically, this data is used to create an internal certificate of analysis to release drug components for drug product manufacturing. Further, you did not have appropriate password protection of your software to prevent unauthorized access to data.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you have password-protected the software for the FTIR system and only the chemist has access to the data. You also stated that the FTIR data is backed up \u003Cstrong>(b)(4)\u003C\u002Fstrong> to an external hard drive and a copy is printed and included as part of the raw material test data package.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate as it did not provide a retrospective review of the integrity of your FTIR, details regarding instrument audit trails and an evaluation of the effectiveness of the computerized system change. It is important to maintain strict controls over CGMP electronic data to ensure all additions, deletions, or modifications of information in your electronic records are authorized and properly documented. Without complete and accurate records, you cannot make appropriate decisions about batch release, stability, and other fundamental factors for ongoing quality assurance.\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers-guidance-industry.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as skin bleaching products.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on your product labels that provide evidence of the intended uses (as defined in 21 CFR 201.128) of your products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n“Indicated for the depigmentation of dark areas of the skin such as age spots, liver spots, freckles, and other unwanted areas of melanin hyperpigmentation.”\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n“Indicated for the depigmentation of dark areas of the skin such as age spots, liver spots, freckles, and other unwanted areas of melanin hyperpigmentation.”\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n“[I]ndicated for the gradual lightening of hyperpigmented skin conditions, such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.”\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n“Indications: Skin lightener”\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n“Indications Skin lightener”\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n“Indications Skin lightener”\u003C\u002Fp>\n\n\u003Cp>All skin bleaching drug products, whether currently labeled as prescription or nonprescription, are considered new drugs as defined in section 201(p)(1) of the FD&amp;C Act.\u003Ca id=\"footnoteref2_clmmcui\" href=\"#footnote2_clmmcui\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa> &nbsp;New drugs may not be legally marketed in the United States absent FDA approval of an application filed in accordance with section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Because no FDA-approved applications are in effect these products, the current marketing of these products violate section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce violates section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong> is misbranded under section 502(c) of the FD&amp;C Act, 21 U.S.C. 352(c). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). This violation is described in more detail below.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for the treatment of acne. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> product label and\u002For labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“Helps to unclog pores with deep cleaning action to prevent future breakouts . . . Drug Facts …. Purpose: Acne Treatment.”&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> is misbranded within the meaning of section 502(c) of the FD&amp;C Act, 21 U.S.C. 352(c), because the label fails to bear a statement of identity as required under 21 CFR 201.61. The label for this product fails to include the established name and general pharmacological category(ies) or principal intended action(s) of the product. For example, the principal display panel should bear “0.5% Salicylic Acid Acne Treatment.”&nbsp;\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration and Listing Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong>) are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for lightening of skin pigmentation.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> product label and labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“indicated for the gradual bleaching of hyperpigmented skin conditions such as chlosma, melasma, freckles, senile lentigines and other unwanted areas of melanin hyperpigmentation.”\u003C\u002Fp>\n\n\u003Cp>Under section 510 of the FD&amp;C Act, as amended, and 21 CFR Part 207, all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA (see 21 U.S.C. 360(j)(1) and 21 CFR 207.41). Current drug listing submissions for \u003Cstrong>(b)(4)\u003C\u002Fstrong> for “Balancer” (NDC \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and “Skin Lightener (NDC \u003Cstrong>(b)(4)\u003C\u002Fstrong>) fail to include Sanitor Corporation as the manufacturing establishment for these products. In addition, these two drug listing submissions, and a third drug listing submission for \u003Cstrong>(b)(4)\u003C\u002Fstrong> (NDC \u003Cstrong>(b)(4)\u003C\u002Fstrong>) reference private label distributor’s drugs. Each registrant must list each drug it manufactures, repacks, or relabels for commercial distribution under the trade name or label of a private label distributor using an NDC that includes such private label distributor's labeler code (21 CFR 207.41(c)(1)) AND each registrant must list each human drug it manufactures, repacks, or relabels using an NDC that includes the registrant's own labeler code, regardless of whether the drug is commercially distributed under the registrant's own label or trade name or under the label or trade name of a private label distributor (21 CFR 207.41(c)(2)). Your firm’s failure to fulfill its drug listing obligations for \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydroquinone \u003Cstrong>(b)(4)\u003C\u002Fstrong>) misbrands these products under section 502(o) of the FD&amp;C Act.&nbsp;\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your executive management oversight and control over the manufacture of drugs is inadequate. Your executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance. You should immediately and comprehensively assess your company’s manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003Cbr>\n&nbsp;&nbsp; &nbsp;\u003Cbr>\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.&nbsp;&nbsp;You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003Cbr>\n&nbsp;&nbsp; &nbsp;\u003Cbr>\n\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge the statement in your response dated June 24, 2021, that you have retained a consultant who is knowledgeable and experienced in CGMP compliance issues with pharmaceuticals, medical devices, cosmetics, and dietary supplements. However, based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant, as set forth in 21 CFR 211.34, with at minimum, appropriate CGMP expertise in overall quality risk management, data integrity, and investigations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.&nbsp;\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your written response should reference unique identifier CMS 616232 and sent electronically to ORAPharm4_Responses@fda.hhs.gov, or mailed to:&nbsp;\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612-2506\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact William V. Millar, Compliance Officer, via email at william.millar@fda.hhs.gov or by phone at (503) 671-9711 Ext. 30.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nCDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_zkcowck\">\u003Ca href=\"#footnoteref1_zkcowck\">1\u003C\u002Fa>See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because your benzalkonium chloride-based hand sanitizer is not consistent with the formulations in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_clmmcui\">\u003Ca href=\"#footnoteref2_clmmcui\">2\u003C\u002Fa>Prior to September 23, 2020, certain drug products intended for skin bleaching, including products that contained 2% or less of hydroquinone, were subject to ongoing over-the-counter (OTC) drug rulemaking. However, beginning on September 23, 2020, all skin-bleaching products that were previously the subject of OTC drug rulemaking are deemed to be a new drug(s) as defined in section 201(p)(1) of the FD&amp;C Act. (See 21 U.S.C. 355G(a)(4). Also see 71 FR 51146.) \u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL CONFIRMED DELIVERY\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jon B. Robinson\n\nRecipient Title\n\nPresident\n\nSanitor Corporation\n\n8400 W. Cerritos Avenue\n\nStanton, CA 90680\n\nUnited States\n\nsanilex@hotmail.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nDear Mr. Robinson:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Sanitor Corporation, FEI 3005871025, at 8400 W. Cerritos Avenue, Stanton, California, from May 25, 2021, to June 3, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nYour firm manufactures (b)(4) and (b)(4) drug products to bleach and\u002For lighten the skin. These products are unapproved new drugs in violation of section 505(a) of the Federal Food & Cosmetic Act (FD&C Act,) 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d). In addition, (b)(4) is a misbranded drug under section 502(c) of the FD&C Act, 21 U.S.C. 352(c). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nIn addition, (b)(4) (Hydroquinone (b)(4)), (b)(4) (Hydroquinone (b)(4)), and (b)(4) (Hydroquinone (b)(4)) are not listed with FDA as required by section 510(j) of the FD&C Act. Failure to properly list a drug product is prohibited and will render a drug misbranded under 21 U.S.C. 331(p), 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nWe reviewed your June 24, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nInadequate investigations\u002FLack of process control\n\nYou contract manufacture over-the-counter drug products including benzalkonium chloride-based hand sanitizer.1 Multiple batches of hand sanitizer drug product failed microbial total plate count (TPC) testing with results of Too Numerous to Count (TNTC). Your quality unit (QU) failed to adequately investigate and identify the root cause for the microbial contamination in your hand sanitizer drug product. Instead of conducting a thorough investigation and implementing corrective action to prevent contamination, your QU:\n\n• Approved the addition of an antimicrobial preservative to batches that initially failed microbial TPC testing, and were then released for distribution by your customer; and\n\n• Approved the addition of an antimicrobial preservative to batches not yet tested for microbial TPC so that they would yield a passing result, and were released for distribution by your customer.\n\nAdditionally, stability samples of a batch of hand sanitizer drug products (previously released without the addition of the preservative) failed the three-month stability test interval for microbial TPC with a result of TNTC. You stated that you notified the customer and recommended a voluntary recall of the drug product. Your customer declined to do so and informed you that the lot was sold and consumed. No further actions were taken.\n\nIn your response, you stated that you have performed a management review with your consultant and determined that your procedures were “inadequately robust and\u002For detailed.” Your response is inadequate in part, because you did not provide a thorough investigation into the microbial failures. You also did not provide adequate details of your consultant’s review and remedial actions. Further, your QU did not exercise its duties and oversight to ensure that future investigations are thorough, including root cause determination and appropriate corrective action strategies.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• Complete investigations into all batches with potential objectionable microbial contamination or an out-of-specification microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\n\n• An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\n\nApproving shipment of drug products before adequate review\n\nYour QU approved drug products for distribution without complete finished product testing. For example, your firm shipped hand sanitizer batch (b)(4) to your customer on June 1, 2020. However, the analytical results were only available as of on June 3, 2020, and the microbiological results were received on June 8, 2020. Your QU approved the certificate of analysis on June 3, 2020, before receiving the microbiological test results and after the batch was shipped to your customer.\n\nIn your response, you stated that you would “transfer” unreleased finished products to your customers under a verbal agreement that the products would not be distributed into interstate commerce until the batch was approved and released by your QU. This practice is unacceptable and increases the risk that drug products that do not meet their quality attributes are distributed to consumers. Complete testing of each batch of drug product before release is required to determine if the drug products you manufacture meet appropriate specifications.\n\nIn response to this letter, provide an independent retrospective review of all hand sanitizer drug products you manufactured to ensure no failing products were distributed. If the review reveals substandard quality drug products were distributed, take rapid corrective actions, such as notifying customers and product recalls.\n\nInadequate stability program\n\nYour QU lacked adequate quality oversight over your stability program. For example, you failed to follow your Package Compatibility Test Program procedure, and place (b)(4) of each product on (b)(4) stability testing to represent the product and process for your hydroquinone (b)(4) drug products.\n\nIn your response, you indicated that the formulation for your hydroquinone (b)(4) drug products is packaged into (b)(4) different products and that all such products were initially placed on stability. Further, you noted that because the formulation, the packaging size, and the material of construction is the same for the (b)(4) products, you are using a bracketing design to conduct the (b)(4) stability testing. However, your response indicated different container closure system designs. Therefore, the bracketing design does not appear scientifically justified. Additionally, this change to add a bracketing approach to your stability program for these products was implemented without adequate change control.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no Stability-indicating methods\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\n• All procedures that describe these and other elements of your remediated stability program.\n\n• A list of expiration dates, with associated justification, for all drug products (e.g., 3 years of real time stability data).\n\nInadequate quality oversight over documentation\n\nDuring the review of a batch record for your (b)(4) hydroquinone (b)(4) drug product, batch (b)(4), our investigators noted that production activities were not recorded contemporaneously. For example, the batch record documented that one employee performed multiple manufacturing steps, such as measuring containers and bulk reconciliation on two separate dates, and a second employee documented the verification of the activities. However, the second employee (verifier) stated to our investigator that they were not at work when these steps were documented as being performed. Your QU oversight does not provide adequate assurance that manufacturing records are accurate, and that production was performed as documented.\n\nIn your response, you acknowledge that good documentation practices were not followed. You also stated that you performed training of all personnel. Your response is inadequate. Your quality system has not adequately ensured the accuracy and integrity of the data to support the safety, effectiveness, and quality of the drugs you manufacture. Without accurate records, you cannot assure appropriate decisions regarding batch release, product stability, and other matters that are fundamental to the ongoing assurance of quality.\n\nIn response to this letter, provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nThe examples above demonstrate the fundamental failure of your QU to perform its roles and responsibilities, but not limited to, oversight over process control, investigation handling, batch review and disposition, and appropriate control of data.\n\nIn response to this letter, provide the following:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. Also, describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nOn September 20, 2021, FDA held a teleconference with you and your consultant. We recommended that you consider removing all of your firm’s hand sanitizer drug products within expiry that were manufactured under the conditions referenced in this letter. On September 21, 2021, you voluntary recalled certain batches of hand sanitizer drug products. On September 22, 2021, FDA notified the public of your lack of adequate controls to prevent microbial contamination at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYou released and distributed multiple reworked batches and newly reformulated batches of your hand sanitizer drug product, without demonstrating the antimicrobial effectiveness testing of the preservative added to the product formulation. Specifically, a batch of your hand sanitizer drug product failed microbial TPC during bulk stage release testing with a result of TNTC. You reworked this batch by adding an antimicrobial preservative. Your deviation report stated that preservative adds microbial stability while not affecting the benzalkonium assay.\n\nIn your response, you stated that you submitted a sample to your contract testing lab to perform antimicrobial effectiveness testing on your hand sanitizer drug product and the results provide evidence of the effectiveness of the addition of the preservative to the formulation.\n\nYour response is inadequate. You did not provide complete laboratory data from your contract laboratory. As per USP \u003C51>, antimicrobial preservatives should not be used as a substitute for good manufacturing practices or solely to reduce the viable microbial population of a nonsterile drug product.\n\nIn your response to this letter, provide the following:\n\n• A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\n\n• A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\n\n• Appropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards.\n\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n• A timeline for performing appropriate process performance qualification for each of your marketed drug products.\n\n• Your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\n3. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nYour (b)(4) Fourier Transform Infrared (FTIR) Spectroscopy computerized system did not have appropriate controls in place to prevent deletion of raw laboratory data. Specifically, this data is used to create an internal certificate of analysis to release drug components for drug product manufacturing. Further, you did not have appropriate password protection of your software to prevent unauthorized access to data.\n\nIn your response, you stated that you have password-protected the software for the FTIR system and only the chemist has access to the data. You also stated that the FTIR data is backed up (b)(4) to an external hard drive and a copy is printed and included as part of the raw material test data package.\n\nYour response is inadequate as it did not provide a retrospective review of the integrity of your FTIR, details regarding instrument audit trails and an evaluation of the effectiveness of the computerized system change. It is important to maintain strict controls over CGMP electronic data to ensure all additions, deletions, or modifications of information in your electronic records are authorized and properly documented. Without complete and accurate records, you cannot make appropriate decisions about batch release, stability, and other fundamental factors for ongoing quality assurance.\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers-guidance-industry.\n\nIn response to this letter, provide the following:\n\n• Comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\nUnapproved New Drug Violations\n\n(b)(4) and (b)(4) are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as skin bleaching products.\n\nExamples of the claims observed on your product labels that provide evidence of the intended uses (as defined in 21 CFR 201.128) of your products include, but may not be limited to, the following:\n\n• (b)(4)\n\n“Indicated for the depigmentation of dark areas of the skin such as age spots, liver spots, freckles, and other unwanted areas of melanin hyperpigmentation.”\n\n• (b)(4)\n\n“Indicated for the depigmentation of dark areas of the skin such as age spots, liver spots, freckles, and other unwanted areas of melanin hyperpigmentation.”\n\n• (b)(4)\n\n“[I]ndicated for the gradual lightening of hyperpigmented skin conditions, such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.”\n\n• (b)(4)\n\n“Indications: Skin lightener”\n\n• (b)(4)\n\n“Indications Skin lightener”\n\n• (b)(4)\n\n“Indications Skin lightener”\n\nAll skin bleaching drug products, whether currently labeled as prescription or nonprescription, are considered new drugs as defined in section 201(p)(1) of the FD&C Act.2 New drugs may not be legally marketed in the United States absent FDA approval of an application filed in accordance with section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Because no FDA-approved applications are in effect these products, the current marketing of these products violate section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce violates section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMisbranding Violations\n\nIn addition, (b)(4) is misbranded under section 502(c) of the FD&C Act, 21 U.S.C. 352(c). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). This violation is described in more detail below.\n\n(b)(4) is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for the treatment of acne.\n\nExamples of claims observed on the (b)(4) product label and\u002For labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Helps to unclog pores with deep cleaning action to prevent future breakouts . . . Drug Facts …. Purpose: Acne Treatment.”\n\n(b)(4) is misbranded within the meaning of section 502(c) of the FD&C Act, 21 U.S.C. 352(c), because the label fails to bear a statement of identity as required under 21 CFR 201.61. The label for this product fails to include the established name and general pharmacological category(ies) or principal intended action(s) of the product. For example, the principal display panel should bear “0.5% Salicylic Acid Acne Treatment.”\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nRegistration and Listing Misbranding Violations\n\n(b)(4) (Hydroquinone (b)(4)), (b)(4) (Hydroquinone (b)(4)), and (b)(4) (Hydroquinone (b)(4)) are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for lightening of skin pigmentation.\n\nExamples of claims observed on the (b)(4), (b)(4), and (b)(4) product label and labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“indicated for the gradual bleaching of hyperpigmented skin conditions such as chlosma, melasma, freckles, senile lentigines and other unwanted areas of melanin hyperpigmentation.”\n\nUnder section 510 of the FD&C Act, as amended, and 21 CFR Part 207, all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA (see 21 U.S.C. 360(j)(1) and 21 CFR 207.41). Current drug listing submissions for (b)(4) for “Balancer” (NDC (b)(4)) and “Skin Lightener (NDC (b)(4)) fail to include Sanitor Corporation as the manufacturing establishment for these products. In addition, these two drug listing submissions, and a third drug listing submission for (b)(4) (NDC (b)(4)) reference private label distributor’s drugs. Each registrant must list each drug it manufactures, repacks, or relabels for commercial distribution under the trade name or label of a private label distributor using an NDC that includes such private label distributor's labeler code (21 CFR 207.41(c)(1)) AND each registrant must list each human drug it manufactures, repacks, or relabels using an NDC that includes the registrant's own labeler code, regardless of whether the drug is commercially distributed under the registrant's own label or trade name or under the label or trade name of a private label distributor (21 CFR 207.41(c)(2)). Your firm’s failure to fulfill its drug listing obligations for (b)(4) (Hydroquinone (b)(4)), (b)(4) (Hydroquinone (b)(4)), and (b)(4) (Hydroquinone (b)(4)) misbrands these products under section 502(o) of the FD&C Act.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nIneffective Quality System\n\nYour executive management oversight and control over the manufacture of drugs is inadequate. Your executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance. You should immediately and comprehensively assess your company’s manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nCGMP Consultant Recommended\n\nWe acknowledge the statement in your response dated June 24, 2021, that you have retained a consultant who is knowledgeable and experienced in CGMP compliance issues with pharmaceuticals, medical devices, cosmetics, and dietary supplements. However, based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant, as set forth in 21 CFR 211.34, with at minimum, appropriate CGMP expertise in overall quality risk management, data integrity, and investigations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written response should reference unique identifier CMS 616232 and sent electronically to ORAPharm4_Responses@fda.hhs.gov, or mailed to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\n19701 Fairchild Road\n\nIrvine, CA 92612-2506\n\nIf you have any questions regarding this letter, please contact William V. Millar, Compliance Officer, via email at william.millar@fda.hhs.gov or by phone at (503) 671-9711 Ext. 30.\n\nSincerely,\n\n\u002Fs\u002F\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\n1See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because your benzalkonium chloride-based hand sanitizer is not consistent with the formulations in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n2Prior to September 23, 2020, certain drug products intended for skin bleaching, including products that contained 2% or less of hydroquinone, were subject to ongoing over-the-counter (OTC) drug rulemaking. However, beginning on September 23, 2020, all skin-bleaching products that were previously the subject of OTC drug rulemaking are deemed to be a new drug(s) as defined in section 201(p)(1) of the FD&C Act. (See 21 U.S.C. 355G(a)(4). Also see 71 FR 51146.)","Sanitor Corporation","sanitor-corporation-616232-11292021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsanitor-corporation-616232-11292021","2026-10-26T08:09:53.733124+00:00","2021-12-14","616232","Mr. Jon B. Robinson","2026-08-20T02:20:52.464+00:00","VIA EMAIL CONFIRMED DELIVERY","2021-11-29",{"id":75,"raw":76,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":44,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":90,"closeout_date":19,"issuing_office":80,"recipient_name":91,"body_fetched_at":92,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},3489,[77,78,79,80,81,13,13,13],"\u003Ctime datetime=\"2021-03-04T15:00:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-18T05:00:00Z\">02\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafalab-inc-611233-02182021\">SafaLab, Inc.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Bradford Weeks\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>SafaLab, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>317 Cascade Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Langley\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@safalab.com\"> info@safalab.com \u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:laura@safalab.com\"> laura@safalab.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: February 18, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your websites at the Internet addresses www.safalab.com and www.weeksmd.com on February 8, 2021. The FDA has observed that your website www.safalab.com offers the product The Prevention 12 Pak—which you also refer to as the Coronavirus Prevention 12 Pak, and which consists of the products SOUL, CORE, Cellular Detox, Turb-O2, Vitamin C (Anti-Oxidant Assist), Vitamin D3 (Light Assist), Glutathione, Selenium, Zinc, Vitamin A, Melatonin, and Iod Assist (Iodine)—for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. In addition, your website www.weeksmd.com directs consumers to www.safalab.com to purchase The Prevention 12 Pak. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your websites that establish the intended use of The Prevention 12 Pak and misleadingly represent it as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cp>On your website www.safalab.com\u002Fproduct\u002Fthe-prevention-12-pak:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The Prevention 12 PAK –\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We are all worried about the spread of the Coronavirus (COVID-19) which kills vulnerable people by Acute Respiratory Distress Syndrome (ARDS). The WHO and FDA claim that there is no cure and no prevention. Integrative medical doctors and their informed patients disagree. Here is the essential 12 Pak to buy for each of your family members and loved ones. To learn the scientific and clinical rationale for each of these essential parts of the Prevention 12 Pak, click HERE to read this article by Bradford S. Weeks, M.D.”\u003C\u002Fp>\n\n\u003Cp>The words “read this article by Bradford S. Weeks, M.D.” hyperlink to your post titled “COVID-19 – how to protect yourself” at www.weeksmd.com\u002F2020\u002F02\u002Fcoronavirus-how-to-protect-yourself\u002F, which includes the following claims:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Here are the Coronavirus 12 Pak items which you can bet your life on.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>1) SOUL – anti-inflammatory…\u003Cbr>\n2) CORE . . .\u003Cbr>\n3) AntiOxidantTMAssist – Vitamin C . . .\u003Cbr>\n4) Cellular Detox . . .\u003Cbr>\n5) Turb-O2TM. . .\u003Cbr>\n6) Melatonin –… anti-viral…\u003Cbr>\n7) Acetylglutathione . . .\u003Cbr>\n8) Light AssistTM– Vit D3 . . .\u003Cbr>\n9) Selenium – powerful anti-viral…\u003Cbr>\n10) Iodine – powerful anti-pathogen…\u003Cbr>\n11) Zinc – membrane protector and anti-viral agent and potentiator of anti-viral drugs…\u003Cbr>\n12) A-25 (Vitamin A palmitate) … powerful safe and effective anti-viral agent”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Under the heading “The Scientific and Clinical Rationale for SAFALAB Corona Prevention 12 Pak Remedies”:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o “Iodine, at appropriate dosages, kills all pathogens which infect the human body:viruses, bacteria, molds, fungi, yeasts and protozoa.”\u003C\u002Fp>\n\n\u003Cp>o “[S]elenium is a potent anti-viral mineral. Selenium facilitates enzymatic processeswhich enhance immune response to viral infections.”\u003C\u002Fp>\n\n\u003Cp>o “But in addition to synchronizing you to the world around you and enhancing your immune system to protect against environmental stressors, melatonin is also a powerful anti-viral agent ......This peer reviewed scientific articleis [sic] just one of many which demonstrates the anti-viral benefits of melatonin”\u003C\u002Fp>\n\n\u003Cp>o “Melatonin and the Coronavirus......Melatonin has been found to inhibit the action of an inflammasome known as NLRP3 – one of the primary inflammasomes involved in the exaggerated immune response seen in critical Coronavirus cases.\u003C\u002Fp>\n\n\u003Cp>Melatonin’s ability to suppress the activation of NLRP3 has been found to:\u003Cbr>\n? Counteract severe inflammatory responses\u003Cbr>\n? Lower production of proinflammatory cytokines\u003Cbr>\n? Lower infiltration of immune cells into lungs\u003Cbr>\n? Reduce lung tissue injury\u003C\u002Fp>\n\n\u003Cp>Melatonin’s role in suppressing the inflammatory response is likely one of the reasons children under the age of 9 rarely present with severe symptoms when infected with Coronavirus. This is because young children can have up to 10 times the peak melatonin levels of older adults.\u003C\u002Fp>\n\n\u003Cp>AND\u003C\u002Fp>\n\n\u003Cp>Here is an impressive study. ‘Melatonin, nitric oxide and ascorbic acid can reduce COVID-19 virulence by inhibiting NLRP3 inflammasomes to stop the perpetuation of cytokine storms.’”\u003C\u002Fp>\n\n\u003Cp>o “Melatonin plays an important role in your immune function. It has antioxidant and mitochondrial-protective functions, and has been shown to be effective against various bacterial and viral infections”\u003C\u002Fp>\n\n\u003Cp>o “The inflammasome NLRP3 is a key culprit in acute respiratory distress syndrome and acute lung injury, both of which are potential outcomes of COVID-19 infection. Melatonin inhibits the activation of NLRP3 inflammasomes, thus offering potential protection against infection”\u003C\u002Fp>\n\n\u003Cp>o “Vitamin D3 is an essential pro-hormone which can help you survive the Coronavirus. Studies show that taking vitamin D3 – the active form of vitamin D results in less severe respiratory infections and also required less antibiotic use.”\u003C\u002Fp>\n\n\u003Cp>o “ACETYLGLUTATHIONE\u003C\u002Fp>\n\n\u003Cp>Glutathione is a powerful . . . anti-inflammatory agent which is tremendously valuable for people suffering from lung diseases and infections of the lung. The Coronavirus creates inflammation and what lowers native glutathione leading to further damage from inflammation. Once infected with the Coronavirus, you need glutathione . . .\u003C\u002Fp>\n\n\u003Cp>RESEARCH ARTICLE\u003C\u002Fp>\n\n\u003Cp>Glutathione-Capped Ag\u003Csub>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fsub>S Nanoclusters Inhibit Coronavirus Proliferation through Blockage of Viral RNA Synthesis and Budding.”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“WHAT TO DO TO PROTECT YOURSELF and your LOVED ONES?\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>HERE IS YOUR ‘TAKE ACTION NOW’ MESSAGE\u003C\u002Fp>\n\n\u003Cp>A competent medical doctor can rescue you if you are infected with the Coronavirus using intravenous infusion. . . But the minimum responsible protection which everyone should have stockpiled in his or her home is the Coronavirus Prevention 12 Pak available HERE from Safalab, Inc. for $568.” [The words “HERE from Safalab” contain a hyperlink that directs consumers to your website www.safalab.com\u002Fproduct\u002Fthe-prevention-12-pak to purchase your product The Prevention 12 Pak.]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“PREVENTION PROTOCOL\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>SOUL – take 1 packet first thing in the morning upon arising and one packet immediately before sleep\u003C\u002Fp>\n\n\u003Cp>CORE – take 1 packet right before breakfast and right before dinner – can mix in 8 oz cold water for taste\u003C\u002Fp>\n\n\u003Cp>Cellular Detox – take 10 drops under the tongue a day\u003C\u002Fp>\n\n\u003Cp>Turb-O2™ – take 1 dropper full in water or juice or on food a day\u003C\u002Fp>\n\n\u003Cp>AntiOxidant Assist (Vitamin C) 1000mg – take 1 three times a day\u003C\u002Fp>\n\n\u003Cp>Melatonin 60mg – take 1 tiny scoop mixed in water or juice a day\u003C\u002Fp>\n\n\u003Cp>Acetylglutathione – take 1 capsule take a day\u003C\u002Fp>\n\n\u003Cp>Vitamin D3 5000 IU – take 1 a day\u003C\u002Fp>\n\n\u003Cp>Methylselenocysteine 200 mcg – take 1 a day\u003C\u002Fp>\n\n\u003Cp>IodAssist (iodine\u002Fdide blend) – take 1 capsule a day\u003C\u002Fp>\n\n\u003Cp>Zinc Monomethionine and Citrate 30mg – take 1 a day\u003C\u002Fp>\n\n\u003Cp>A-25 (Vitamin A palmitate) 2500 IU – take 1 a day”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“ACUTE TREATMENT PROTOCOL (onset of cough, sore throat, headache, fever etc)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>SOUL – take 1 packet 4x a day -first thing in the morning upon arising, one at 10 AM, one at 4 PM and one packet immediately before sleep\u003C\u002Fp>\n\n\u003Cp>CORE – take 4x a day – 2 packets right before breakfast and 2 packets right before dinner – can mix in 8 oz cold water for taste\u003C\u002Fp>\n\n\u003Cp>Cellular Detox – take 10 drops under the tongue twice a day\u003C\u002Fp>\n\n\u003Cp>Turb-O2™ – take 1 dropper full in water or juice or on food twice a day\u003C\u002Fp>\n\n\u003Cp>AntiOxidant Assist (Vitamin C) 1000mg – take 1-3 tables [sic] three times a day or more – push this dosage to bowel tolerance. When stools are loose, cut back.\u003C\u002Fp>\n\n\u003Cp>Melatonin 60mg – take 1 tiny scoop mixed in water or juice a day three times a day\u003C\u002Fp>\n\n\u003Cp>Acetylglutathione – take 1 capsule twice a day\u003C\u002Fp>\n\n\u003Cp>Vitamin D3 5000 IU – take a 10 at first sign of cough or fever for 2 days then reduce to 1 a day\u003C\u002Fp>\n\n\u003Cp>Methylselenocysteine 200 mcg – take 1 twice a day\u003C\u002Fp>\n\n\u003Cp>IodAssist (iodine\u002Fdide blend) – take 1 capsule three times a day\u003C\u002Fp>\n\n\u003Cp>Zinc Monomethionine and Citrate 30mg – take 1 twice a day\u003Cbr>\n\u003Cbr>\nA-25 (Vitamin A palmitate) 2500 IU – take 6 at first sign of fever\u002Fcough and 6 again before sleep and repeat that high dose for no more than 4 days then drop back to 1 a day”\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CFSAN@fda.hhs.gov\u003C\u002Fstrong> and \u003Cstrong>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them , If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at \u003Cstrong>COVID-19-Task-Force-CFSAN@fda.hhs.gov\u003C\u002Fstrong> and \u003Cstrong>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $43,792 per violation. Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at \u003Cspan>202-326-3088\u003C\u002Fspan>.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William A. Correll\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>___________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at&nbsp;https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDr. Bradford Weeks\n\nSafaLab, Inc.\n\n317 Cascade Ave.\n\nLangley, WA 98260\n\nUnited States\n\ninfo@safalab.com\n\nlaura@safalab.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nDate: February 18, 2021\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your websites at the Internet addresses www.safalab.com and www.weeksmd.com on February 8, 2021. The FDA has observed that your website www.safalab.com offers the product The Prevention 12 Pak—which you also refer to as the Coronavirus Prevention 12 Pak, and which consists of the products SOUL, CORE, Cellular Detox, Turb-O2, Vitamin C (Anti-Oxidant Assist), Vitamin D3 (Light Assist), Glutathione, Selenium, Zinc, Vitamin A, Melatonin, and Iod Assist (Iodine)—for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. In addition, your website www.weeksmd.com directs consumers to www.safalab.com to purchase The Prevention 12 Pak. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your websites that establish the intended use of The Prevention 12 Pak and misleadingly represent it as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\nOn your website www.safalab.com\u002Fproduct\u002Fthe-prevention-12-pak:\n\n“The Prevention 12 PAK –\n\nWe are all worried about the spread of the Coronavirus (COVID-19) which kills vulnerable people by Acute Respiratory Distress Syndrome (ARDS). The WHO and FDA claim that there is no cure and no prevention. Integrative medical doctors and their informed patients disagree. Here is the essential 12 Pak to buy for each of your family members and loved ones. To learn the scientific and clinical rationale for each of these essential parts of the Prevention 12 Pak, click HERE to read this article by Bradford S. Weeks, M.D.”\n\nThe words “read this article by Bradford S. Weeks, M.D.” hyperlink to your post titled “COVID-19 – how to protect yourself” at www.weeksmd.com\u002F2020\u002F02\u002Fcoronavirus-how-to-protect-yourself\u002F, which includes the following claims:\n\n“Here are the Coronavirus 12 Pak items which you can bet your life on.\n\n1) SOUL – anti-inflammatory…\n\n2) CORE . . .\n\n3) AntiOxidantTMAssist – Vitamin C . . .\n\n4) Cellular Detox . . .\n\n5) Turb-O2TM. . .\n\n6) Melatonin –… anti-viral…\n\n7) Acetylglutathione . . .\n\n8) Light AssistTM– Vit D3 . . .\n\n9) Selenium – powerful anti-viral…\n\n10) Iodine – powerful anti-pathogen…\n\n11) Zinc – membrane protector and anti-viral agent and potentiator of anti-viral drugs…\n\n12) A-25 (Vitamin A palmitate) … powerful safe and effective anti-viral agent”\n\nUnder the heading “The Scientific and Clinical Rationale for SAFALAB Corona Prevention 12 Pak Remedies”:\n\no “Iodine, at appropriate dosages, kills all pathogens which infect the human body:viruses, bacteria, molds, fungi, yeasts and protozoa.”\n\no “[S]elenium is a potent anti-viral mineral. Selenium facilitates enzymatic processeswhich enhance immune response to viral infections.”\n\no “But in addition to synchronizing you to the world around you and enhancing your immune system to protect against environmental stressors, melatonin is also a powerful anti-viral agent ......This peer reviewed scientific articleis [sic] just one of many which demonstrates the anti-viral benefits of melatonin”\n\no “Melatonin and the Coronavirus......Melatonin has been found to inhibit the action of an inflammasome known as NLRP3 – one of the primary inflammasomes involved in the exaggerated immune response seen in critical Coronavirus cases.\n\nMelatonin’s ability to suppress the activation of NLRP3 has been found to:\n\n? Counteract severe inflammatory responses\n\n? Lower production of proinflammatory cytokines\n\n? Lower infiltration of immune cells into lungs\n\n? Reduce lung tissue injury\n\nMelatonin’s role in suppressing the inflammatory response is likely one of the reasons children under the age of 9 rarely present with severe symptoms when infected with Coronavirus. This is because young children can have up to 10 times the peak melatonin levels of older adults.\n\nAND\n\nHere is an impressive study. ‘Melatonin, nitric oxide and ascorbic acid can reduce COVID-19 virulence by inhibiting NLRP3 inflammasomes to stop the perpetuation of cytokine storms.’”\n\no “Melatonin plays an important role in your immune function. It has antioxidant and mitochondrial-protective functions, and has been shown to be effective against various bacterial and viral infections”\n\no “The inflammasome NLRP3 is a key culprit in acute respiratory distress syndrome and acute lung injury, both of which are potential outcomes of COVID-19 infection. Melatonin inhibits the activation of NLRP3 inflammasomes, thus offering potential protection against infection”\n\no “Vitamin D3 is an essential pro-hormone which can help you survive the Coronavirus. Studies show that taking vitamin D3 – the active form of vitamin D results in less severe respiratory infections and also required less antibiotic use.”\n\no “ACETYLGLUTATHIONE\n\nGlutathione is a powerful . . . anti-inflammatory agent which is tremendously valuable for people suffering from lung diseases and infections of the lung. The Coronavirus creates inflammation and what lowers native glutathione leading to further damage from inflammation. Once infected with the Coronavirus, you need glutathione . . .\n\nRESEARCH ARTICLE\n\nGlutathione-Capped Ag2S Nanoclusters Inhibit Coronavirus Proliferation through Blockage of Viral RNA Synthesis and Budding.”\n\n“WHAT TO DO TO PROTECT YOURSELF and your LOVED ONES?\n\nHERE IS YOUR ‘TAKE ACTION NOW’ MESSAGE\n\nA competent medical doctor can rescue you if you are infected with the Coronavirus using intravenous infusion. . . But the minimum responsible protection which everyone should have stockpiled in his or her home is the Coronavirus Prevention 12 Pak available HERE from Safalab, Inc. for $568.” [The words “HERE from Safalab” contain a hyperlink that directs consumers to your website www.safalab.com\u002Fproduct\u002Fthe-prevention-12-pak to purchase your product The Prevention 12 Pak.]\n\n“PREVENTION PROTOCOL\n\nSOUL – take 1 packet first thing in the morning upon arising and one packet immediately before sleep\n\nCORE – take 1 packet right before breakfast and right before dinner – can mix in 8 oz cold water for taste\n\nCellular Detox – take 10 drops under the tongue a day\n\nTurb-O2™ – take 1 dropper full in water or juice or on food a day\n\nAntiOxidant Assist (Vitamin C) 1000mg – take 1 three times a day\n\nMelatonin 60mg – take 1 tiny scoop mixed in water or juice a day\n\nAcetylglutathione – take 1 capsule take a day\n\nVitamin D3 5000 IU – take 1 a day\n\nMethylselenocysteine 200 mcg – take 1 a day\n\nIodAssist (iodine\u002Fdide blend) – take 1 capsule a day\n\nZinc Monomethionine and Citrate 30mg – take 1 a day\n\nA-25 (Vitamin A palmitate) 2500 IU – take 1 a day”\n\n“ACUTE TREATMENT PROTOCOL (onset of cough, sore throat, headache, fever etc)\n\nSOUL – take 1 packet 4x a day -first thing in the morning upon arising, one at 10 AM, one at 4 PM and one packet immediately before sleep\n\nCORE – take 4x a day – 2 packets right before breakfast and 2 packets right before dinner – can mix in 8 oz cold water for taste\n\nCellular Detox – take 10 drops under the tongue twice a day\n\nTurb-O2™ – take 1 dropper full in water or juice or on food twice a day\n\nAntiOxidant Assist (Vitamin C) 1000mg – take 1-3 tables [sic] three times a day or more – push this dosage to bowel tolerance. When stools are loose, cut back.\n\nMelatonin 60mg – take 1 tiny scoop mixed in water or juice a day three times a day\n\nAcetylglutathione – take 1 capsule twice a day\n\nVitamin D3 5000 IU – take a 10 at first sign of cough or fever for 2 days then reduce to 1 a day\n\nMethylselenocysteine 200 mcg – take 1 twice a day\n\nIodAssist (iodine\u002Fdide blend) – take 1 capsule three times a day\n\nZinc Monomethionine and Citrate 30mg – take 1 twice a day\n\nA-25 (Vitamin A palmitate) 2500 IU – take 6 at first sign of fever\u002Fcough and 6 again before sleep and repeat that high dose for no more than 4 days then drop back to 1 a day”\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CFSAN@fda.hhs.gov and COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them , If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CFSAN@fda.hhs.gov and COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nIn addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $43,792 per violation. Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam A. Correll\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n___________________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","SafaLab, Inc.","safalab-inc-611233-02182021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafalab-inc-611233-02182021","2026-10-26T08:09:52.492379+00:00","2021-03-04","611233","DrugsFood & Beverages","Dr. Bradford Weeks","2026-08-20T03:19:22.211+00:00","2021-02-18",{"id":95,"raw":96,"subject":100,"body_html":101,"body_text":102,"firm_name":103,"letter_id":104,"created_at":105,"fei_number":19,"letter_url":106,"updated_at":107,"action_type":22,"case_status":23,"posted_date":108,"marcs_cms_no":109,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":110,"body_fetched_at":111,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":112,"medical_device_id":19,"response_letter_date":19},219,[97,98,99,11,100,13,13,13],"\u003Ctime datetime=\"2026-04-21T04:00:00Z\">04\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-17T04:00:00Z\">04\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsanotize-727784-04172026\">SaNOtize\u003C\u002Fa>","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mikael Svensson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SaNOtize\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1-8755 Ash Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Vancouver\u003C\u002Fspan> \u003Cspan>BC\u003C\u002Fspan> \u003Cspan>V6P 6T3\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@sanotize.com\"> info@sanotize.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>\u003Cu>WARNING LETTER\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>April 17, 2026\u003C\u002Fp>\u003Cp>RE: 727784\u003C\u002Fp>\u003Cp>Mikael Svensson:\u003C\u002Fp>\u003Cp>This letter is to advise you that on February 17, 2026 the United States Food and Drug Administration (FDA) reviewed your product labeling, including your websites at the internet addresses https:\u002F\u002Fwww.nowonder.com\u002F and https:\u002F\u002Fsanotize.com\u002F where your “NOWONDER™ Nasal Cleanser” is available for purchase in the United States without a prescription.\u003C\u002Fp>\u003Cp>“NOWONDER™ Nasal Cleanser” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your “NOWONDER™ Nasal Cleanser” is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “NOWONDER™ Nasal Cleanser” product labeling, including your websites listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>&nbsp; “When people around you are sick, boost your body’s natural defenses with our Nasal Wellness Spray, powered by the wonder of Nitric Oxide. Nitric Oxide is naturally produced by your immune system and helps support your ability to fight germs that can cause the common cold, flu and other illnesses.” [from your product website]\u003C\u002Fp>\u003Cp>&nbsp; “Powered by the Wonder of Nitric Oxide…Nitric Oxide safely and effectively improves your ability to fight common disease-causing germs and pathogens.” [from your product website]\u003C\u002Fp>\u003Cp>&nbsp; “The Wonder of Nitric Oxide…Clinically proven to safely and effectively kill viruses and bacteria…Nitric oxide is a powerful, naturally occurring molecule that plays a critical role in supporting your immune defense and promoting overall health. Its antiviral and antimicrobial properties help protect against common infections and illnesses.” [from your product website]\u003C\u002Fp>\u003Cp>&nbsp; “Effective…Clinical studies demonstrate that nitric oxide inhibits the replication of harmful viruses, including influenza and SARS-CoV-2, showcasing its powerful antiviral capabilities.” [from your product website]\u003C\u002Fp>\u003Cp>&nbsp; “Effective cleansing whenever exposed to harmful elements such as bacteria, viruses…” [from your product label]\u003C\u002Fp>\u003Cp>Your “NOWONDER™ Nasal Cleanser” drug product is not generally recognized as safe and effective (GRASE)\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> for use under the conditions prescribed, recommended, or suggested in its labeling and is therefore a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for this drug product. Accordingly, “NOWONDER™ Nasal Cleanser” is a new drug in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). The introduction or delivery for introduction of such a product into interstate commerce violates section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “727784” in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:\u003Cbr>Mikael Svensson, CEO\u003Cbr>NoWonder, Inc.\u003Cbr>8180 South 700 East\u003Cbr>Suite 350\u003Cbr>Sandy, UT 84070\u003Cbr>info@nowonder.com\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “NOWONDER™ Nasal Cleanser” drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMikael Svensson\n\nRecipient Title\n\nCEO\n\nSaNOtize\n\n1-8755 Ash Street\n\nVancouver BC V6P 6T3\n\nCanada\n\ninfo@sanotize.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nApril 17, 2026\nRE: 727784\nMikael Svensson:\nThis letter is to advise you that on February 17, 2026 the United States Food and Drug Administration (FDA) reviewed your product labeling, including your websites at the internet addresses https:\u002F\u002Fwww.nowonder.com\u002F and https:\u002F\u002Fsanotize.com\u002F where your “NOWONDER™ Nasal Cleanser” is available for purchase in the United States without a prescription.\n“NOWONDER™ Nasal Cleanser” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d). These violations are described in more detail below.\nUnapproved New Drug Violations\nYour “NOWONDER™ Nasal Cleanser” is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\nExamples from the “NOWONDER™ Nasal Cleanser” product labeling, including your websites listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\n“When people around you are sick, boost your body’s natural defenses with our Nasal Wellness Spray, powered by the wonder of Nitric Oxide. Nitric Oxide is naturally produced by your immune system and helps support your ability to fight germs that can cause the common cold, flu and other illnesses.” [from your product website]\n“Powered by the Wonder of Nitric Oxide…Nitric Oxide safely and effectively improves your ability to fight common disease-causing germs and pathogens.” [from your product website]\n“The Wonder of Nitric Oxide…Clinically proven to safely and effectively kill viruses and bacteria…Nitric oxide is a powerful, naturally occurring molecule that plays a critical role in supporting your immune defense and promoting overall health. Its antiviral and antimicrobial properties help protect against common infections and illnesses.” [from your product website]\n“Effective…Clinical studies demonstrate that nitric oxide inhibits the replication of harmful viruses, including influenza and SARS-CoV-2, showcasing its powerful antiviral capabilities.” [from your product website]\n“Effective cleansing whenever exposed to harmful elements such as bacteria, viruses…” [from your product label]\nYour “NOWONDER™ Nasal Cleanser” drug product is not generally recognized as safe and effective (GRASE)1 for use under the conditions prescribed, recommended, or suggested in its labeling and is therefore a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for this drug product. Accordingly, “NOWONDER™ Nasal Cleanser” is a new drug in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). The introduction or delivery for introduction of such a product into interstate commerce violates section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “727784” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc:\nMikael Svensson, CEO\nNoWonder, Inc.\n8180 South 700 East\nSuite 350\nSandy, UT 84070\ninfo@nowonder.com\n___________________\n1 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “NOWONDER™ Nasal Cleanser” drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.","SaNOtize","sanotize-727784-04172026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsanotize-727784-04172026","2026-10-26T08:09:53.813774+00:00","2026-04-21","727784","Mikael Svensson","2026-08-19T04:46:49.668+00:00","2026-04-17",{"id":114,"raw":115,"subject":39,"body_html":119,"body_text":120,"firm_name":121,"letter_id":122,"created_at":123,"fei_number":19,"letter_url":124,"updated_at":125,"action_type":22,"case_status":23,"posted_date":126,"marcs_cms_no":127,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":128,"body_fetched_at":129,"delivery_method":52,"recipient_title":19,"reference_number":130,"action_taken_date":126,"medical_device_id":19,"response_letter_date":19},1813,[116,117,118,38,39,13,13,13],"\u003Ctime datetime=\"2023-10-05T18:00:00Z\">10\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-05T04:00:00Z\">10\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafa-goods-llc-665079-10052023\">Safa Goods, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2300956\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Haitham Shriteh\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Safa Goods, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1212 Market Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Port Charlotte\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33953\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:adam@safagoods.com\"> adam@safagoods.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 5, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Shriteh:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Safa Goods, LLC distributes Electronic Nicotine Delivery Systems (ENDS) products for commercial distribution in the United States, and that the ENDS products are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you sell and\u002For distribute to customers in the United States ENDS products that lack a marketing authorization order, including: EB Design BC5000 Blue Razz Ice.\u003C\u002Fp>\n\n\u003Cp>The ENDS product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300956, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2300956\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMr. Haitham Shriteh\n\nRecipient Title\n\nCo-Owner\n\nSafa Goods, LLC\n\n1212 Market Circle\n\nPort Charlotte, FL 33953\n\nUnited States\n\nadam@safagoods.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 5, 2023\n\nWARNING LETTER\n\nDear Mr. Shriteh:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Safa Goods, LLC distributes Electronic Nicotine Delivery Systems (ENDS) products for commercial distribution in the United States, and that the ENDS products are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you sell and\u002For distribute to customers in the United States ENDS products that lack a marketing authorization order, including: EB Design BC5000 Blue Razz Ice.\n\nThe ENDS product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300956, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Safa Goods, LLC","safa-goods-llc-665079-10052023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafa-goods-llc-665079-10052023","2026-10-26T08:09:52.456428+00:00","2023-10-05","665079","Mr. Haitham Shriteh","2026-08-20T00:37:42.43+00:00","ER2300956",{"id":132,"raw":133,"subject":136,"body_html":137,"body_text":138,"firm_name":139,"letter_id":140,"created_at":141,"fei_number":19,"letter_url":142,"updated_at":143,"action_type":22,"case_status":23,"posted_date":144,"marcs_cms_no":145,"product_type":146,"closeout_date":19,"issuing_office":80,"recipient_name":147,"body_fetched_at":148,"delivery_method":149,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},3520,[134,78,135,80,136,13,13,13],"\u003Ctime datetime=\"2021-02-19T17:00:00Z\">02\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsana-group-llc-612256-02182021\">SANA Group LLC\u003C\u002Fa>","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason W. Harris\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SANA Group LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1200 E. Woodhurst S-200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Springfield\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>65804\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>RE: [CMS:612256]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear Mr. Harris,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.sleepsana.com\u003Cspan>, \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>in December 2020 and has determined that you take orders there for your Sleep Sana “Sleep Drops” and “Sleep Shots” products. The claims on your website establish that your \u003Cspan>products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">\u003Cspan>\u003Cspan>www.fda.gov\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Examples of some of the\u003C\u002Fspan> \u003Cspan>website claims that provide evidence that your “Sleep Drops” and “Sleep Shots” are intended for use as drugs include:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>On the webpage for Sleep Sana “Sleep Drops” and “Sleep Shots” ingredients: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"GABA (an ingredient in your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan>\u003Cspan> is taken by mouth for relieving anxiety, ... and treating attention deficit hyperactivity disorder (ADHD). It is also used for ... stabilizing blood pressure, and relieving pain.\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"L-tryptophan (an ingredient in your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan>\u003Cspan> is used for insomnia, sleep apnea, depression, anxiety, facial pain, a severe form of premenstrual syndrome called premenstrual dysphoric disorder (PMDD), ... attention deficit-hyperactivity disorder (ADHD), Tourette's syndrome....\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>&nbsp;\"Valerian (an ingredient in your \u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan> is most commonly used for sleep disorders, especially the inability to sleep (insomnia).\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\"[Y]our body may produce melatonin (an ingredient in your \u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan> either earlier or later in the day than usual. This change can lead to symptoms of seasonal affective disorder (SAD), or winter depression.\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your “Sleep Drops” and “Sleep Shots” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. \u003Cspan>§§ \u003C\u002Fspan>331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. \u003Cspan>§ \u003C\u002Fspan>201.5).&nbsp; Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your “Sleep Drops” and “Sleep Shots” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for their intended purposes. Accordingly, your “Sleep Drops” and “Sleep Shots” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. \u003Cspan>§\u003C\u002Fspan> 331(a)]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take prompt action to address the violates cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations.&nbsp; Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.&nbsp; If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. Your reply should be sent via e-mail to \u003C\u002Fspan>\u003Ca href=\"mailto:FDAAdvisory@fda.hhs.gov\">\u003Cspan>FDAAdvisory@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>William A. Correll Jr.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Center for Food Safety and Applied Nutrition\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJason W. Harris\n\nRecipient Title\n\nOwner\n\nSANA Group LLC\n\n1200 E. Woodhurst S-200\n\nSpringfield, MO 65804\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nRE: [CMS:612256]\n\nDear Mr. Harris,\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.sleepsana.com, in December 2020 and has determined that you take orders there for your Sleep Sana “Sleep Drops” and “Sleep Shots” products. The claims on your website establish that your products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your “Sleep Drops” and “Sleep Shots” are intended for use as drugs include:\n\nOn the webpage for Sleep Sana “Sleep Drops” and “Sleep Shots” ingredients:\n\n\"GABA (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is taken by mouth for relieving anxiety, ... and treating attention deficit hyperactivity disorder (ADHD). It is also used for ... stabilizing blood pressure, and relieving pain.\"\n\n\"L-tryptophan (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is used for insomnia, sleep apnea, depression, anxiety, facial pain, a severe form of premenstrual syndrome called premenstrual dysphoric disorder (PMDD), ... attention deficit-hyperactivity disorder (ADHD), Tourette's syndrome....\"\n\n\"Valerian (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is most commonly used for sleep disorders, especially the inability to sleep (insomnia).\"\n\n\"[Y]our body may produce melatonin (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) either earlier or later in the day than usual. This change can lead to symptoms of seasonal affective disorder (SAD), or winter depression.\"\n\nYour “Sleep Drops” and “Sleep Shots” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Sleep Drops” and “Sleep Shots” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for their intended purposes. Accordingly, your “Sleep Drops” and “Sleep Shots” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address the violates cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. Your reply should be sent via e-mail to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam A. Correll Jr.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration","SANA Group LLC","sana-group-llc-612256-02182021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsana-group-llc-612256-02182021","2026-10-26T08:09:53.390359+00:00","2021-02-19","612256","Food & Beverages","Jason W. Harris","2026-08-20T03:22:28.818+00:00","Via Overnight Delivery",{"id":151,"raw":152,"subject":100,"body_html":156,"body_text":157,"firm_name":158,"letter_id":159,"created_at":105,"fei_number":19,"letter_url":160,"updated_at":161,"action_type":22,"case_status":23,"posted_date":162,"marcs_cms_no":163,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":164,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":165,"medical_device_id":19,"response_letter_date":19},392,[153,154,155,11,100,13,13,13],"\u003Ctime datetime=\"2025-12-23T05:00:00Z\">12\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-12T05:00:00Z\">12\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftitan-sarms-llc-719645-12122025\">TITAN SARMS LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>TITAN SARMS LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>191 University Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Denver\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80206\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:contact@titansarms.com\"> contact@titansarms.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jedbigelow@hopkinsroden.com\"> jedbigelow@hopkinsroden.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 12, 2025\u003C\u002Fp>\u003Cp>TITAN SARMS LLC\u003Cbr>Jedediah Bigelow, Legal Counsel\u003Cbr>30 N. Gould St., Suite R\u003Cbr>Sheridan, WY 82801\u003C\u002Fp>\u003Cp>RE: 719645\u003C\u002Fp>\u003Cp>TITAN SARMS LLC:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fwww.titansarms.com\u002F in November 2025. The FDA has observed that you offer products marketed on your firm’s website as selective androgen receptor modulators (SARMs) including, but not limited to, “LGD-4033” (also referred to on your website as Ligandrol), “RAD-140” (also referred to on your website as Testolone), “S-4” (also referred to on your website as Andarine), and “YK-11” (also referred to on your website as Myostatin Inhibitor) (hereinafter products marketed as SARMs) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>FDA has safety concerns about products that contain SARMs. Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs. SARMs also have the potential to increase the risk of heart attack and stroke.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products as “Research-grade compound[s]” and “RESEARCH-ONLY PURPOSE,” evidence obtained from your product labeling, including your website, establishes that your products are intended to be drugs for human use. Based on a review of your website, your products marketed as SARMs are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>LGD-4033 Ligandrol\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>On the webpage https:\u002F\u002Fwww.titansarms.com\u002Fproduct\u002Fligandrol-capsules:\u003Cbr>“SARMS STATS\u003Cbr>o CARDIAC ENDURANCE\u003Cbr>o PROTEIN SYNTHESIS\u003Cbr>o MUSCULAR BULK\u003Cbr>o MUSCULAR RECOVERY\u003Cbr>o FAT OXIDATION\u003Cbr>o MAXIMAL MASS\u003Cbr>o MUSCULAR ENDURANCE”\u003C\u002Fli>\u003Cli>“Ligandrol is a Selective Androgen Receptor Modulator (SARM) — known for its potent anabolic activity in muscle and bone tissue.\u003Cbr>In research settings, it has been shown to:\u003Cbr>o Increase lean body mass even at low doses.\u003Cbr>o Enhance muscle strength and endurance capacity.\u003Cbr>o Aid recovery from musculoskeletal injury.”\u003C\u002Fli>\u003Cli>“MUSCLE HYPERTROPHY:\u003Cbr>o Clinical studies have shown Ligandrol to significantly increase lean muscle mass in healthy adults within just weeks of administration.”\u003C\u002Fli>\u003Cli>“STRENGTH GAINS:\u003Cbr>o Participants in research trials have demonstrated measurable improvements in lifting strength and muscular endurance.”\u003C\u002Fli>\u003Cli>“RECOVERY SUPPORT:\u003Cbr>o By promoting anabolic signaling, Ligandrol can aid in tissue repair following injury or intense training.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>RAD-140 Testolone\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fwww.titansarms.com\u002Fproduct\u002Frad140-capsules:\u003C\u002Fp>\u003Cul>\u003Cli>“RAD-140 (Testolone) is a Selective Androgen Receptor Modulator (SARM) — studied for its high anabolic-to-androgenic ratio and potential neuroprotective benefits.\u003Cbr>In research settings, it has been shown to:\u003Cbr>o Stimulate significant muscle growth.\u003Cbr>o Enhance strength and power output.\u003Cbr>o Exhibit neuroprotective effects in research models.”\u003C\u002Fli>\u003Cli>“Lean Muscle Retention\u003Cbr>o RAD-140 (Testolone) has been observed to induce robust gains in lean muscle mass, even at low research dosages.”\u003C\u002Fli>\u003Cli>“PERFORMANCE ENHANCEMENT:\u003Cbr>o Its anabolic effects contribute to improvements in maximal strength and explosive power.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>S-4 Andarine\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fwww.titansarms.com\u002Fproduct\u002Fs4-capsules:\u003C\u002Fp>\u003Cul>\u003Cli>“S-4 (Andarine) is a Selective Androgen Receptor Modulator (SARM) — originally developed for muscle wasting and osteoporosis.\u003Cbr>In research settings, it has been shown to:\u003Cbr>o Increase muscle mass while reducing fat.\u003Cbr>o Support bone density improvements.\u003Cbr>o Enhance muscular definition and vascularity.”\u003C\u002Fli>\u003Cli>“BODY COMPOSITION:\u003Cbr>o S-4 is often studied for its ability to reduce fat mass while preserving or increasing lean muscle.”\u003C\u002Fli>\u003Cli>“BONE HEALTH:\u003Cbr>o Research shows positive effects on bone strength and mineral density.”\u003C\u002Fli>\u003Cli>“AESTHETIC BENEFITS:\u003Cbr>o May enhance muscle hardness and vascularity in trained subjects.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>YK-11 Myostatin inhibitor\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fwww.titansarms.com\u002Fproduct\u002Fyk11-capsules:\u003C\u002Fp>\u003Cul>\u003Cli>“YK-11 is a Selective Androgen Receptor Modulator (SARM) — unique for also acting as a myostatin inhibitor, potentially unlocking greater muscle growth.\u003Cbr>In research settings, it has been shown to:\u003Cbr>o Increase muscle cell differentiation and size.\u003Cbr>o Reduce myostatin activity in muscle tissue.\u003Cbr>o Support rapid strength development.”\u003C\u002Fli>\u003Cli>“MYOSTATIN INHIBITION:\u003Cbr>o YK-11’s ability to down regulate myostatin expression may allow for greater muscle hypertrophy than SARMs without this effect.”\u003C\u002Fli>\u003Cli>“ACCELERATED STRENGTH:\u003Cbr>o Research models indicate faster increases in muscular strength compared to baseline.”\u003C\u002Fli>\u003Cli>“CELLULAR GROWTH:\u003Cbr>o By promoting follistatin expression, YK-11 supports muscle cell development and repair.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, your website includes images of athletic men and women exercising or lifting weights.\u003C\u002Fp>\u003Cp>Your products marketed as SARMs are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “719645” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002Ffda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nTITAN SARMS LLC\n\n191 University Blvd.\n\nDenver, CO 80206\n\nUnited States\n\ncontact@titansarms.com\n\njedbigelow@hopkinsroden.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nDecember 12, 2025\nTITAN SARMS LLC\nJedediah Bigelow, Legal Counsel\n30 N. Gould St., Suite R\nSheridan, WY 82801\nRE: 719645\nTITAN SARMS LLC:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fwww.titansarms.com\u002F in November 2025. The FDA has observed that you offer products marketed on your firm’s website as selective androgen receptor modulators (SARMs) including, but not limited to, “LGD-4033” (also referred to on your website as Ligandrol), “RAD-140” (also referred to on your website as Testolone), “S-4” (also referred to on your website as Andarine), and “YK-11” (also referred to on your website as Myostatin Inhibitor) (hereinafter products marketed as SARMs) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nFDA has safety concerns about products that contain SARMs. Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs. SARMs also have the potential to increase the risk of heart attack and stroke.1\nDespite statements on your product labeling marketing your products as “Research-grade compound[s]” and “RESEARCH-ONLY PURPOSE,” evidence obtained from your product labeling, including your website, establishes that your products are intended to be drugs for human use. Based on a review of your website, your products marketed as SARMs are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nLGD-4033 Ligandrol\nOn the webpage https:\u002F\u002Fwww.titansarms.com\u002Fproduct\u002Fligandrol-capsules:\n“SARMS STATS\no CARDIAC ENDURANCE\no PROTEIN SYNTHESIS\no MUSCULAR BULK\no MUSCULAR RECOVERY\no FAT OXIDATION\no MAXIMAL MASS\no MUSCULAR ENDURANCE”\n“Ligandrol is a Selective Androgen Receptor Modulator (SARM) — known for its potent anabolic activity in muscle and bone tissue.\nIn research settings, it has been shown to:\no Increase lean body mass even at low doses.\no Enhance muscle strength and endurance capacity.\no Aid recovery from musculoskeletal injury.”\n“MUSCLE HYPERTROPHY:\no Clinical studies have shown Ligandrol to significantly increase lean muscle mass in healthy adults within just weeks of administration.”\n“STRENGTH GAINS:\no Participants in research trials have demonstrated measurable improvements in lifting strength and muscular endurance.”\n“RECOVERY SUPPORT:\no By promoting anabolic signaling, Ligandrol can aid in tissue repair following injury or intense training.”\nRAD-140 Testolone\nOn the webpage https:\u002F\u002Fwww.titansarms.com\u002Fproduct\u002Frad140-capsules:\n“RAD-140 (Testolone) is a Selective Androgen Receptor Modulator (SARM) — studied for its high anabolic-to-androgenic ratio and potential neuroprotective benefits.\nIn research settings, it has been shown to:\no Stimulate significant muscle growth.\no Enhance strength and power output.\no Exhibit neuroprotective effects in research models.”\n“Lean Muscle Retention\no RAD-140 (Testolone) has been observed to induce robust gains in lean muscle mass, even at low research dosages.”\n“PERFORMANCE ENHANCEMENT:\no Its anabolic effects contribute to improvements in maximal strength and explosive power.”\nS-4 Andarine\nOn the webpage https:\u002F\u002Fwww.titansarms.com\u002Fproduct\u002Fs4-capsules:\n“S-4 (Andarine) is a Selective Androgen Receptor Modulator (SARM) — originally developed for muscle wasting and osteoporosis.\nIn research settings, it has been shown to:\no Increase muscle mass while reducing fat.\no Support bone density improvements.\no Enhance muscular definition and vascularity.”\n“BODY COMPOSITION:\no S-4 is often studied for its ability to reduce fat mass while preserving or increasing lean muscle.”\n“BONE HEALTH:\no Research shows positive effects on bone strength and mineral density.”\n“AESTHETIC BENEFITS:\no May enhance muscle hardness and vascularity in trained subjects.”\nYK-11 Myostatin inhibitor\nOn the webpage https:\u002F\u002Fwww.titansarms.com\u002Fproduct\u002Fyk11-capsules:\n“YK-11 is a Selective Androgen Receptor Modulator (SARM) — unique for also acting as a myostatin inhibitor, potentially unlocking greater muscle growth.\nIn research settings, it has been shown to:\no Increase muscle cell differentiation and size.\no Reduce myostatin activity in muscle tissue.\no Support rapid strength development.”\n“MYOSTATIN INHIBITION:\no YK-11’s ability to down regulate myostatin expression may allow for greater muscle hypertrophy than SARMs without this effect.”\n“ACCELERATED STRENGTH:\no Research models indicate faster increases in muscular strength compared to baseline.”\n“CELLULAR GROWTH:\no By promoting follistatin expression, YK-11 supports muscle cell development and repair.”\nIn addition, your website includes images of athletic men and women exercising or lifting weights.\nYour products marketed as SARMs are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “719645” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n_____________________\n1 See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002Ffda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults.","TITAN SARMS LLC","titan-sarms-llc-719645-12122025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftitan-sarms-llc-719645-12122025","2026-10-26T08:10:12.616965+00:00","2025-12-23","719645","2026-08-19T07:20:33.767+00:00","2025-12-12",{"id":167,"raw":168,"subject":39,"body_html":172,"body_text":173,"firm_name":174,"letter_id":175,"created_at":176,"fei_number":19,"letter_url":177,"updated_at":178,"action_type":22,"case_status":23,"posted_date":179,"marcs_cms_no":180,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":181,"body_fetched_at":182,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":179,"medical_device_id":19,"response_letter_date":19},2023,[169,170,171,38,39,13,13,13],"\u003Ctime datetime=\"2023-06-29T17:00:00Z\">06\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-29T04:00:00Z\">06\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-salon-661991-06292023\">Vapor Salon\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Troy D. Johnston II\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vapor Salon\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4380 Western Center Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Worth\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76137\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@vaporsalon.com\"> sales@vaporsalon.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 29, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Johnston:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Vapor Salon manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: VS Premium Eliquid Cloud Walker 0.6%.\u003C\u002Fp>\n\n\u003Cp>The e-liquid product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the product listed in this Warning Letter. This product and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300844, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nTroy D. Johnston II\n\nRecipient Title\n\nOwner\n\nVapor Salon\n\n4380 Western Center Boulevard\n\nFort Worth, TX 76137\n\nUnited States\n\nsales@vaporsalon.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 29, 2023\n\nWARNING LETTER\n\nDear Mr. Johnston:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Vapor Salon manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: VS Premium Eliquid Cloud Walker 0.6%.\n\nThe e-liquid product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the product listed in this Warning Letter. This product and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300844, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Vapor Salon","vapor-salon-661991-06292023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-salon-661991-06292023","2026-10-26T08:10:24.932341+00:00","2023-06-29","661991","Troy D. Johnston II","2026-08-20T00:59:43.441+00:00",{"id":184,"raw":185,"subject":190,"body_html":191,"body_text":192,"firm_name":193,"letter_id":194,"created_at":176,"fei_number":19,"letter_url":195,"updated_at":196,"action_type":22,"case_status":23,"posted_date":197,"marcs_cms_no":198,"product_type":146,"closeout_date":19,"issuing_office":189,"recipient_name":199,"body_fetched_at":200,"delivery_method":201,"recipient_title":19,"reference_number":19,"action_taken_date":202,"medical_device_id":19,"response_letter_date":19},2191,[186,187,188,189,190,13,13,13],"\u003Ctime datetime=\"2023-02-28T14:20:00Z\">02\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-29T05:00:00Z\">12\u002F29\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsalazar-sons-corp-643562-12292022\">Salazar &amp; Sons Corp\u003C\u002Fa>","Division of Southwest Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Aaron A Salazar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Salazar &amp; Sons Corp\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2071 E Nebraska Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dinuba\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>93618-9345\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 29, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 643562\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Aaron A Salazar,\u003C\u002Fp>\n\n\u003Cp>On July 12, 2022 to August 26, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Salazar &amp; Sons Corp located at 2071 E Nebraska Ave, Dinuba, CA 93618-9345. We also conducted an inspection on June 17, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on August 26, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Persian limes imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Watermelon imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Jicama imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You import fresh produce that is “covered produce” as defined in 21 CFR 112.3. As an importer of covered produce, you must demonstrate that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&amp;C Act (21 U.S.C. 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Brian Erickson, Compliance Officer, 9777 Via de la Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, you may contact Brian Erickson via email at brian.erickson@fda.hhs.gov. Please reference CMS # 643562 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003Cbr>\n\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nDivision Director\u003Cbr>\nDivision of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAaron A Salazar\n\nRecipient Title\n\nOwner\n\nSalazar & Sons Corp\n\n2071 E Nebraska Ave\n\nDinuba, CA 93618-9345\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nDecember 29, 2022\n\nWARNING LETTER\n\nRe: CMS # 643562\n\nDear Mr. Aaron A Salazar,\n\nOn July 12, 2022 to August 26, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Salazar & Sons Corp located at 2071 E Nebraska Ave, Dinuba, CA 93618-9345. We also conducted an inspection on June 17, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on August 26, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including:\n\nPersian limes imported from (b)(4)\n\nWatermelon imported from (b)(4)\n\nJicama imported from (b)(4)\n\nYou import fresh produce that is “covered produce” as defined in 21 CFR 112.3. As an importer of covered produce, you must demonstrate that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&C Act (21 U.S.C. 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Brian Erickson, Compliance Officer, 9777 Via de la Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, you may contact Brian Erickson via email at brian.erickson@fda.hhs.gov. Please reference CMS # 643562 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nDivision Director\n\nDivision of Southwest Imports","Salazar & Sons Corp","salazar-sons-corp-643562-12292022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsalazar-sons-corp-643562-12292022","2026-10-26T08:09:52.97235+00:00","2023-02-28","643562","Aaron A Salazar","2026-08-20T01:14:10.159+00:00","Via Express Delivery","2022-12-29",{"id":204,"raw":205,"subject":212,"body_html":213,"body_text":214,"firm_name":215,"letter_id":216,"created_at":176,"fei_number":19,"letter_url":217,"updated_at":218,"action_type":22,"case_status":219,"posted_date":220,"marcs_cms_no":221,"product_type":146,"closeout_date":222,"issuing_office":223,"recipient_name":224,"body_fetched_at":225,"delivery_method":226,"recipient_title":19,"reference_number":227,"action_taken_date":228,"medical_device_id":19,"response_letter_date":19},2304,[206,207,208,209,210,13,211,13],"\u003Ctime datetime=\"2022-12-06T14:20:00Z\">12\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-23T04:00:00Z\">09\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-usa-llc-629821-09232022\">Saffron USA LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations East IV ","Unapproved New Drugs\u002FMisbranded \u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-usa-llc-629821-01092023\">\u003Ctime datetime=\"2023-01-17T05:00:00Z\">01\u002F17\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>17-HAFE4-WL-07\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Farangis Sedaghat\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Saffron USA LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>504 Spring Island Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orlando\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32828\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ftsedaghat@yahoo.com\"> ftsedaghat@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East IV \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 23, 2022\u003Cbr>\n\u003Cbr>\nDear Ms. Sedaghat:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fsaffronusa.com in September 2022 and has determined that you take orders there for the products Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>1. Product: Allergy Blend\u003C\u002Fp>\n\n\u003Cp>On your product website https:\u002F\u002Fsaffronusa.com for Allergy Blend and under Health Benefits, your webpage shows:\u003Cbr>\n- Product name “Allergy Blend”\u003Cbr>\n- “A natural blend for Allergy relief”\u003Cbr>\n- “Upper respiratory tract infections”\u003Cbr>\n- “Coughs, Bronchitis”\u003Cbr>\n- “Asthma”\u003C\u002Fp>\n\n\u003Cp>2. Product: Chamomile Tea Petals\u003C\u002Fp>\n\n\u003Cp>On your product website https:\u002F\u002Fsaffronusa.com for Chamomile Tea Petals under Health Benefits, your webpage shows:\u003Cbr>\n- “Treating diabetes”\u003Cbr>\n- “Slowing or preventing osteoporosis”\u003Cbr>\n- “Reducing inflammation”\u003Cbr>\n- “Cancer”\u003Cbr>\n- “[T]reating cold symptoms”\u003C\u002Fp>\n\n\u003Cp>3. Product: Diabetic Support Blend\u003C\u002Fp>\n\n\u003Cp>On your product website https:\u002F\u002Fsaffronusa.com for Diabetic Support Blend and under Health Benefits, your webpage shows:\u003Cbr>\n- Product name “Diabetic Support Blend”\u003Cbr>\n- “A natural blend to help combat Diabetic”\u003Cbr>\n- “Have Cancer-Fighting Properties”\u003Cbr>\n- “Decrease Cholesterol Levels…”\u003C\u002Fp>\n\n\u003Cp>4. Product: Orange Blast Tea\u003C\u002Fp>\n\n\u003Cp>On your product website https:\u002F\u002Fsaffronusa.com for Orange Blast Tea under Health Benefits, your webpage shows:\u003Cbr>\n- “Prevents skin damage.”\u003Cbr>\n- “Keeps blood pressure under check.”\u003Cbr>\n- “Lowers cholesterol.”\u003Cbr>\n- “Controls blood sugar level.”\u003Cbr>\n- “Lowers the risk of cancer.”\u003C\u002Fp>\n\n\u003Cp>5. Product: “Saffron Loose Tea”\u003C\u002Fp>\n\n\u003Cp>On your product website https:\u002F\u002Fsaffronusa.com for Saffron Loose Tea under Health Benefits, your webpage shows:\u003Cbr>\n- “Fights Anxiety”\u003Cbr>\n- “Cancer prevention”\u003Cbr>\n- “Help insomnia”\u003C\u002Fp>\n\n\u003Cp>Your Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be directed to the Food and Drug Administration, attention to: Mr. Ramon A. Hernández, District Director, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. You may email a copy of your response with appropriate attachments to email address: orahafeast4firmresponses@fda.hhs.gov . Please ensure your firm name, Firm Establishment Identifier (FEI) and establishment address are included in the correspondence. If you have any questions regarding this letter, please contact Ms. Gina Eng, Compliance Officer, at (561) 416-1065 ext. 1114 or via email at Gina.Eng@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ramon A. Hernandez\u003Cbr>\nDistrict Director | FDA San Juan District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food\u003Cbr>\nOperations\u003Cbr>\nEast Division 4\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n17-HAFE4-WL-07\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Farangis Sedaghat\n\nRecipient Title\n\nManager\n\nSaffron USA LLC\n\n504 Spring Island Way\n\nOrlando, FL 32828\n\nUnited States\n\nftsedaghat@yahoo.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East IV\n\nUnited States\n\nWARNING LETTER\n\nSeptember 23, 2022\n\nDear Ms. Sedaghat:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fsaffronusa.com in September 2022 and has determined that you take orders there for the products Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\n1. Product: Allergy Blend\n\nOn your product website https:\u002F\u002Fsaffronusa.com for Allergy Blend and under Health Benefits, your webpage shows:\n\n- Product name “Allergy Blend”\n\n- “A natural blend for Allergy relief”\n\n- “Upper respiratory tract infections”\n\n- “Coughs, Bronchitis”\n\n- “Asthma”\n\n2. Product: Chamomile Tea Petals\n\nOn your product website https:\u002F\u002Fsaffronusa.com for Chamomile Tea Petals under Health Benefits, your webpage shows:\n\n- “Treating diabetes”\n\n- “Slowing or preventing osteoporosis”\n\n- “Reducing inflammation”\n\n- “Cancer”\n\n- “[T]reating cold symptoms”\n\n3. Product: Diabetic Support Blend\n\nOn your product website https:\u002F\u002Fsaffronusa.com for Diabetic Support Blend and under Health Benefits, your webpage shows:\n\n- Product name “Diabetic Support Blend”\n\n- “A natural blend to help combat Diabetic”\n\n- “Have Cancer-Fighting Properties”\n\n- “Decrease Cholesterol Levels…”\n\n4. Product: Orange Blast Tea\n\nOn your product website https:\u002F\u002Fsaffronusa.com for Orange Blast Tea under Health Benefits, your webpage shows:\n\n- “Prevents skin damage.”\n\n- “Keeps blood pressure under check.”\n\n- “Lowers cholesterol.”\n\n- “Controls blood sugar level.”\n\n- “Lowers the risk of cancer.”\n\n5. Product: “Saffron Loose Tea”\n\nOn your product website https:\u002F\u002Fsaffronusa.com for Saffron Loose Tea under Health Benefits, your webpage shows:\n\n- “Fights Anxiety”\n\n- “Cancer prevention”\n\n- “Help insomnia”\n\nYour Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be directed to the Food and Drug Administration, attention to: Mr. Ramon A. Hernández, District Director, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. You may email a copy of your response with appropriate attachments to email address: orahafeast4firmresponses@fda.hhs.gov . Please ensure your firm name, Firm Establishment Identifier (FEI) and establishment address are included in the correspondence. If you have any questions regarding this letter, please contact Ms. Gina Eng, Compliance Officer, at (561) 416-1065 ext. 1114 or via email at Gina.Eng@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRamon A. Hernandez\n\nDistrict Director | FDA San Juan District\n\nProgram Division Director\n\nOffice of Human and Animal Food\n\nOperations\n\nEast Division 4","Saffron USA LLC","saffron-usa-llc-629821-09232022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-usa-llc-629821-09232022","2026-10-26T08:09:52.690735+00:00","Closed Out","2022-12-06","629821","2023-01-17","Division of Human and Animal Food Operations East IV","Ms. Farangis Sedaghat","2026-08-20T01:23:29.186+00:00","VIA Electronic Mail","17-HAFE4-WL-07","2022-09-23",{"id":230,"raw":231,"subject":39,"body_html":235,"body_text":236,"firm_name":237,"letter_id":238,"created_at":18,"fei_number":19,"letter_url":239,"updated_at":240,"action_type":22,"case_status":23,"posted_date":241,"marcs_cms_no":242,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":19,"body_fetched_at":243,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":244,"medical_device_id":19,"response_letter_date":19},1271,[232,233,234,38,39,13,13,13],"\u003Ctime datetime=\"2024-09-10T13:20:00Z\">09\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-05T04:00:00Z\">09\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmaster-sales-llc-691754-09052024\">Master Sales LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Master Sales LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1315 Calder Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>McLean\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>22101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 5, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>To Whom It May Concern:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Master Sales LLC manufactures, sells and\u002For distributes hookah products to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including hookah products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including hookah products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotinetake-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture and offer for sale or distribution to customers in the United States hookah products that lack a marketing authorization order, including: NU Tobacco Strong Mint 250g.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2401073, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>John E. Verbeten\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc: Master Sales LLC\u003Cbr>\n16780 Oakmont Avenue\u003Cbr>\nGaithersburg, MD 20877\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nMaster Sales LLC\n\n1315 Calder Road\n\nMcLean, VA 22101\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 5, 2024\n\nWARNING LETTER\n\nTo Whom It May Concern:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Master Sales LLC manufactures, sells and\u002For distributes hookah products to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including hookah products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including hookah products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotinetake-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture and offer for sale or distribution to customers in the United States hookah products that lack a marketing authorization order, including: NU Tobacco Strong Mint 250g.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2401073, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJohn E. Verbeten\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc: Master Sales LLC\n\n16780 Oakmont Avenue\n\nGaithersburg, MD 20877","Master Sales LLC","master-sales-llc-691754-09052024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmaster-sales-llc-691754-09052024","2026-10-26T08:09:21.50445+00:00","2024-09-10","691754","2026-08-19T23:49:35.225+00:00","2024-09-05",{"id":246,"raw":247,"subject":252,"body_html":253,"body_text":254,"firm_name":255,"letter_id":256,"created_at":123,"fei_number":19,"letter_url":257,"updated_at":258,"action_type":22,"case_status":23,"posted_date":259,"marcs_cms_no":260,"product_type":26,"closeout_date":19,"issuing_office":251,"recipient_name":261,"body_fetched_at":262,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":263,"medical_device_id":19,"response_letter_date":19},1578,[248,249,250,251,252,13,13,13],"\u003Ctime datetime=\"2024-03-05T14:20:00Z\">03\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-28T05:00:00Z\">02\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnative-salts-llc-674277-02282024\">Native Salts LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Andrew J. Pickens\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Native Salts LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>515 N. Noble St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chicago\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60642\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:wakeup@nativesalts.com\"> wakeup@nativesalts.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 28, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Pickens:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of an over-the-counter (OTC) stimulant drug product. The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.nativesalts.com on November 15, 2023. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fnativesalts1, where you direct consumers to your website, https:\u002F\u002Fwww.nativesalts.com to purchase your product.\u003C\u002Fp>\n\n\u003Cp>“\u003Cu>N\u003C\u002Fu>, Native Salts” drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“\u003Cu>N\u003C\u002Fu>, Native Salts” is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a stimulant drug product.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on the “\u003Cu>N\u003C\u002Fu>, Native Salts” labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “Instant Alertness[:] Native Salts provide a quick and easy way to regain focus, improve energy, and get back to things that matter most to you.” [from your product’s website at https:\u002F\u002Fwww.nativesalts.com\u002F]\u003Cbr>\n\u003Cbr>\n&nbsp; &nbsp; “Native Salts is an all-natural, handmade smelling salts that you can actually use everyday and does not only produce an energizing and alert sensation but also smells pleasant and aromatic.” [from your product’s website at https:\u002F\u002Fwww.nativesalts.com\u002F]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “Is Native Salts healthy? Native Salts are composed of simple organic ingredients to provide a natural, refreshing, &amp; alert sensation. They are an invigorating way to stay alert without caffeine. …. We take pride that our smelling salts are all-natural, aromatic, while keeping you alert!” [from your product’s website at https:\u002F\u002Fwww.nativesalts.com\u002Ffaq]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “Is Ammonia in Native Salts dangerous? …Smelling salts, like Native Salts, contain a heavily diluted form of ammonium, which gives off ammonia gas. Think of it like this, inhaling pure ammonia is like doing a belly flop off of an Olympic high dive. It's going to hurt a lot. Inhaling Native Salts is like doing a cannonball off the side of the pool. It's going to wake you up and give you a tiny boost of adrenaline.” [from your product’s website at https:\u002F\u002Fwww.nativesalts.com\u002Ffaq]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “When Should I Use Native Salts? They are most commonly used during sports games or at the gym for strenuous exercise and to aid in getting that last rep up. The great part about Native Salts is that it can be used in a variety of settings outside of lifting and intense workouts. In most scenarios, it can give you a quick jolt of energy when you're tired while avoiding caffeine. Its other usages can vary from waking up in the morning, before a yoga class, a work meeting, a big exam, or even while out at a bar with friends.” [from your product’s website at https:\u002F\u002Fwww.nativesalts.com\u002Ffaq]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “When you want a pick-me-up, but don’t want a caffeine crash.” [from a post on your Facebook webpage, dated 8\u002F21\u002F2023, at https:\u002F\u002Fwww.facebook.com\u002Fnativesalts1]\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, your “\u003Cu>N\u003C\u002Fu>, Native Salts” drug product, containing the ingredients ammonium, eucalyptus oil, peppermint oil, polymer crystals, glycerin, and water, is intended for use as a stimulant drug product. Specifically, this product is intended for use as both a reflex stimulant (i.e., smelling salt, ammonia inhalant) and, more generally, as a stimulant to help restore mental alertness or wakefulness. As described below, this stimulant drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>In general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from the FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for your firm’s “\u003Cu>N\u003C\u002Fu>, Native Salts” drug product.\u003C\u002Fp>\n\n\u003Cp>“\u003Cu>N\u003C\u002Fu>, Native Salts” is a reflex stimulant drug product subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, this reflex stimulant drug product falls under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), because it is subject to a determination to be not GRASE in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330. The term “smelling salt” typically is used to refer to an ammonia aromatic preparation used as a reflex stimulant.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> On June 19, 2008, FDA issued a proposed rule (73 FR 34895)\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not GRASE or are misbranded. This June 19, 2008 proposed rule is the most recent applicable FDA proposal issued under 21 CFR Part 330 with respect to ammonia as a reflex stimulant in OTC drug products. Thus, “\u003Cu>N\u003C\u002Fu>, Native Salts” is deemed to be a new drug under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Even if “\u003Cu>N\u003C\u002Fu>, Native Salts” was not marketed as a reflex stimulant drug product and was only marketed as a more general stimulant drug product, your product would still not meet the requirements under section 505G, under which it would be deemed to be GRASE and not a new drug.\u003C\u002Fp>\n\n\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, nonprescription stimulant drug products are GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph, M011: Stimulant Drug Products for Over-the-Counter Human Use (hereinafter M011).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, your “\u003Cu>N\u003C\u002Fu>, Native Salts” stimulant drug product does not conform to the conditions of use specified in Monograph M011 because your nonprescription product is formulated with the active ingredient ammonium\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and labeled with directions for intranasal administration, neither of which comply with the applicable conditions of use specified in M011, as set forth in the final administrative order OTC000025. Therefore, even if “\u003Cu>N\u003C\u002Fu>, Native Salts” was marketed as only a general stimulant drug product, it would not meet the requirements under section 505G, under which it would be GRASE and not a new drug.\u003C\u002Fp>\n\n\u003Cp>In addition, the FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “\u003Cu>N\u003C\u002Fu>, Native Salts” is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Further, as noted above, there are no approved applications in effect for this product. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Lastly, “\u003Cu>N\u003C\u002Fu>, Native Salts” is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nOffice Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Merriam Webster’s dictionary defines “smelling salts” as “a usually scented aromatic preparation of ammonium carbonate and ammonia water used as a stimulant and restorative.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On June 19, 2008, FDA issued a proposed rule (73 FR 34895) setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not generally recognized as safe and effective (GRASE) and are misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA did not determine that it was in the interest of public health to extend the period during which any drug subject to section 505G(a)(4) may be marketed without an approved new drug application.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> OTC stimulant drug products are subject to Over-the-Counter Monograph M011: Stimulant Drug Products for Over-the-Counter Human Use, as set forth in a final administrative order established under section 505G of the FD&amp;C Act. (Over-the-Counter Monograph M011 Final Administrative Order (OTC000025))\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> M011 specifies that caffeine, in a form suitable for oral administration, is the only acceptable active ingredient for use as a stimulant under the order.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAndrew J. Pickens\n\nNative Salts LLC\n\n515 N. Noble St.\n\nChicago, IL 60642\n\nUnited States\n\nwakeup@nativesalts.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nFebruary 28, 2024\n\nDear Mr. Pickens:\n\nThis letter concerns your firm’s distribution of an over-the-counter (OTC) stimulant drug product. The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.nativesalts.com on November 15, 2023. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fnativesalts1, where you direct consumers to your website, https:\u002F\u002Fwww.nativesalts.com to purchase your product.\n\n“N, Native Salts” drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\n“N, Native Salts” is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a stimulant drug product.\n\nExamples of the claims observed on the “N, Native Salts” labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Instant Alertness[:] Native Salts provide a quick and easy way to regain focus, improve energy, and get back to things that matter most to you.” [from your product’s website at https:\u002F\u002Fwww.nativesalts.com\u002F]\n\n“Native Salts is an all-natural, handmade smelling salts that you can actually use everyday and does not only produce an energizing and alert sensation but also smells pleasant and aromatic.” [from your product’s website at https:\u002F\u002Fwww.nativesalts.com\u002F]\n\n“Is Native Salts healthy? Native Salts are composed of simple organic ingredients to provide a natural, refreshing, & alert sensation. They are an invigorating way to stay alert without caffeine. …. We take pride that our smelling salts are all-natural, aromatic, while keeping you alert!” [from your product’s website at https:\u002F\u002Fwww.nativesalts.com\u002Ffaq]\n\n“Is Ammonia in Native Salts dangerous? …Smelling salts, like Native Salts, contain a heavily diluted form of ammonium, which gives off ammonia gas. Think of it like this, inhaling pure ammonia is like doing a belly flop off of an Olympic high dive. It's going to hurt a lot. Inhaling Native Salts is like doing a cannonball off the side of the pool. It's going to wake you up and give you a tiny boost of adrenaline.” [from your product’s website at https:\u002F\u002Fwww.nativesalts.com\u002Ffaq]\n\n“When Should I Use Native Salts? They are most commonly used during sports games or at the gym for strenuous exercise and to aid in getting that last rep up. The great part about Native Salts is that it can be used in a variety of settings outside of lifting and intense workouts. In most scenarios, it can give you a quick jolt of energy when you're tired while avoiding caffeine. Its other usages can vary from waking up in the morning, before a yoga class, a work meeting, a big exam, or even while out at a bar with friends.” [from your product’s website at https:\u002F\u002Fwww.nativesalts.com\u002Ffaq]\n\n“When you want a pick-me-up, but don’t want a caffeine crash.” [from a post on your Facebook webpage, dated 8\u002F21\u002F2023, at https:\u002F\u002Fwww.facebook.com\u002Fnativesalts1]\n\nBased on the above labeling claims, your “N, Native Salts” drug product, containing the ingredients ammonium, eucalyptus oil, peppermint oil, polymer crystals, glycerin, and water, is intended for use as a stimulant drug product. Specifically, this product is intended for use as both a reflex stimulant (i.e., smelling salt, ammonia inhalant) and, more generally, as a stimulant to help restore mental alertness or wakefulness. As described below, this stimulant drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nIn general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from the FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for your firm’s “N, Native Salts” drug product.\n\n“N, Native Salts” is a reflex stimulant drug product subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, this reflex stimulant drug product falls under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), because it is subject to a determination to be not GRASE in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330. The term “smelling salt” typically is used to refer to an ammonia aromatic preparation used as a reflex stimulant.1 On June 19, 2008, FDA issued a proposed rule (73 FR 34895)2 setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not GRASE or are misbranded. This June 19, 2008 proposed rule is the most recent applicable FDA proposal issued under 21 CFR Part 330 with respect to ammonia as a reflex stimulant in OTC drug products. Thus, “N, Native Salts” is deemed to be a new drug under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.3\n\nEven if “N, Native Salts” was not marketed as a reflex stimulant drug product and was only marketed as a more general stimulant drug product, your product would still not meet the requirements under section 505G, under which it would be deemed to be GRASE and not a new drug.\n\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, nonprescription stimulant drug products are GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph, M011: Stimulant Drug Products for Over-the-Counter Human Use (hereinafter M011).4 However, your “N, Native Salts” stimulant drug product does not conform to the conditions of use specified in Monograph M011 because your nonprescription product is formulated with the active ingredient ammonium5 and labeled with directions for intranasal administration, neither of which comply with the applicable conditions of use specified in M011, as set forth in the final administrative order OTC000025. Therefore, even if “N, Native Salts” was marketed as only a general stimulant drug product, it would not meet the requirements under section 505G, under which it would be GRASE and not a new drug.\n\nIn addition, the FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “N, Native Salts” is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Further, as noted above, there are no approved applications in effect for this product. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nLastly, “N, Native Salts” is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nOffice Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n___________________________\n\n1 Merriam Webster’s dictionary defines “smelling salts” as “a usually scented aromatic preparation of ammonium carbonate and ammonia water used as a stimulant and restorative.”\n\n2 On June 19, 2008, FDA issued a proposed rule (73 FR 34895) setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not generally recognized as safe and effective (GRASE) and are misbranded.\n\n3 FDA did not determine that it was in the interest of public health to extend the period during which any drug subject to section 505G(a)(4) may be marketed without an approved new drug application.\n\n4 OTC stimulant drug products are subject to Over-the-Counter Monograph M011: Stimulant Drug Products for Over-the-Counter Human Use, as set forth in a final administrative order established under section 505G of the FD&C Act. (Over-the-Counter Monograph M011 Final Administrative Order (OTC000025))\n\n5 M011 specifies that caffeine, in a form suitable for oral administration, is the only acceptable active ingredient for use as a stimulant under the order.","Native Salts LLC","native-salts-llc-674277-02282024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnative-salts-llc-674277-02282024","2026-10-26T08:09:30.290631+00:00","2024-03-05","674277","Andrew J. Pickens","2026-08-20T00:16:08.322+00:00","2024-02-28",{"id":265,"raw":266,"subject":39,"body_html":270,"body_text":271,"firm_name":272,"letter_id":273,"created_at":65,"fei_number":19,"letter_url":274,"updated_at":275,"action_type":22,"case_status":23,"posted_date":276,"marcs_cms_no":277,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":278,"body_fetched_at":279,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":276,"medical_device_id":19,"response_letter_date":19},2527,[267,268,269,38,39,13,13,13],"\u003Ctime datetime=\"2022-08-08T19:00:00Z\">08\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-08T04:00:00Z\">08\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-saloon-llc-637302-08082022\">Vapor-Saloon, LLC \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Stanley Aaron Sheffield\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vapor-Saloon, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6305 Wesley Street, Suite 101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Greenville\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75402\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vsgreenville@gmail.com\"> vsgreenville@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 8, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Sheffield:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Vapor-Saloon, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Elysium 3mg 120ml, Dragonlily 6mg 120ml, BLUEBONNET 3mg 120ml, and Caribou 3mg 60ml.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003867, on September 10, 2020. However, FDA issued a negative action for STN PM0003867 in the form of a Refuse To File determination on April 7, 2022, which covers 447 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003867 that resulted in a Refuse To File determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200595, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\naaronsheffield@hotmail.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nStanley Aaron Sheffield\n\nRecipient Title\n\nOwner\n\nVapor-Saloon, LLC\n\n6305 Wesley Street, Suite 101\n\nGreenville, TX 75402\n\nUnited States\n\nvsgreenville@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 8, 2022\n\nWARNING LETTER\n\nDear Mr. Sheffield:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Vapor-Saloon, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Elysium 3mg 120ml, Dragonlily 6mg 120ml, BLUEBONNET 3mg 120ml, and Caribou 3mg 60ml.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003867, on September 10, 2020. However, FDA issued a negative action for STN PM0003867 in the form of a Refuse To File determination on April 7, 2022, which covers 447 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003867 that resulted in a Refuse To File determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200595, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc:\n\naaronsheffield@hotmail.com","Vapor-Saloon, LLC","vapor-saloon-llc-637302-08082022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-saloon-llc-637302-08082022","2026-10-26T08:10:24.99301+00:00","2022-08-08","637302","Stanley Aaron Sheffield","2026-08-20T01:41:30.435+00:00",{"id":281,"raw":282,"subject":190,"body_html":287,"body_text":288,"firm_name":289,"letter_id":290,"created_at":65,"fei_number":19,"letter_url":291,"updated_at":292,"action_type":22,"case_status":23,"posted_date":293,"marcs_cms_no":294,"product_type":146,"closeout_date":19,"issuing_office":286,"recipient_name":295,"body_fetched_at":296,"delivery_method":201,"recipient_title":19,"reference_number":19,"action_taken_date":297,"medical_device_id":19,"response_letter_date":19},2924,[283,284,285,286,190,13,13,13],"\u003Ctime datetime=\"2022-01-18T14:20:00Z\">01\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-11T05:00:00Z\">01\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaad-trading-inc-614485-01112022\">Saad Trading Inc.\u003C\u002Fa>","Division of Northern Border Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Khalil Saad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Saad Trading Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16322 W Warren Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Detroit\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48228-3703\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northern Border Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Date: January 11, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 614485\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Khalil Saad:\u003C\u002Fp>\n\n\u003Cp>From August 18 to September 21, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of Saad Trading Inc. located at 14311 W. Warren Ave., Dearborn MI 48126-1458. We also conducted an inspection on March 4, 17, 24 and 30, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Our March 2021 inspection was initiated as a result of an FDA sample finding of \u003Cem>Salmonella\u003C\u002Fem> in a plain halva product imported from your foreign supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In response to the FDA sample finding, we acknowledge that you voluntarily destroyed all the plain halva product in this shipment. Further on March 4, 2021, this product and foreign manufacturer combination was placed on the Red List of Import Alert 99-19 “Detention Without Physical Examination of Food Products Due to the Presence of \u003Cem>Salmonella\u003C\u002Fem>.” At the conclusion of our inspection, an FDA-483a was issued and we acknowledge receipt of your response dated April 14, 2021 containing various food safety documents from your foreign suppliers.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the following foods you import: plain halva from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, tahina from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and dried okra from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. To date we have not received a response to the issued FDA 483a.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You must promptly investigate to determine whether your FSVP is adequate and, when appropriate, modify your FSVP when you became aware that a foreign supplier of food that you import does not produce food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, or produces food that is adulterated under section 402 or misbranded under section 403(w) (if applicable), as required by 21 CFR 1.508(b). Further, you must document any investigations, corrective actions, and changes to your FSVP that you undertake. Your firm failed to document any review and assessment of your foreign supplier’s food safety plan after a sample of plain halva product you imported from your approved foreign supplier, \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>tested positive for \u003Cem>Salmonella\u003C\u002Fem>. In addition, you did not modify your FSVP or document any changes you made to your FSVP as appropriate, after you determined that your foreign supplier was not in compliance with the applicable food safety requirements as a result of the positive sample.\u003C\u002Fp>\n\n\u003Cp>In your FDA Form 483a response dated April 18, 2021, you stated that you “contacted the supplier and notify them with this issue and ask them to re-evaluate the whole process specially the hazard process and what the correction steps will be taken to prevent any issue in the future. . ..” However, we were unable to verify this investigation or any corrective actions during our most recent follow-up inspection because you did not provide FDA with documentation of any action you have taken as a result of the positive sample, such as your documented review and assessment of a recent audit report that includes a review of your foreign supplier’s environmental monitoring program.\u003C\u002Fp>\n\n\u003Cp>2. You must conduct a hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504(a). Although you may meet this requirement by reviewing and assessing the hazard analysis conducted by another entity using a qualified individual, you must document your review and assessment of that hazard analysis, including documenting that the hazard analysis was conducted by a qualified individual (21 CFR 1.504(d)). During our inspection, you provided a hazard analysis from your foreign suppliers for the tahina from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> and for the halva from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide documentation that you have reviewed and assessed your foreign supplier’s hazard analyses or that this review and assessment was conducted by a qualified individual.\u003C\u002Fp>\n\n\u003Cp>3. You must approve your foreign suppliers on the basis of an evaluation of your foreign supplier’s performance and the risk posed by the food, in accordance with 21 CFR 1.505(a) for products you import. Moreover, your evaluation must consider applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, as required by 21 CFR 1.505(a)(1)(iii)(B) and you must document this evaluation in accordance with 21 CFR 1.505(a)(2). You did not document any evaluation of the performance of your foreign suppliers,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> or your consideration of these suppliers’ compliance with the applicable FDA food safety regulations.\u003C\u002Fp>\n\n\u003Cp>4. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506. Specifically, you did not establish written procedures for ensuring that appropriate supplier verification activities are conducted in accordance with 21 CFR 1.506(b) and you did not document your determination of the appropriate supplier verification activity in accordance with 21 CFR 1.506(d) for the tahini imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; the plain halva imported from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> and the okra imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your revised FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Mark Kaspar, Compliance Officer, DNBI, USFDA, 550 W Jackson, 15th Floor Chicago IL 60661. If you have any questions regarding this letter, you may contact Mark Kaspar via email at mark.kaspar@fda.hhs.gov. Please reference CMS # 614485 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Keith J. Jasukaitis\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Northern Border Imports\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Mr. Khalil Saad, President\u003Cbr>\nSaad Trading, Inc.\u003Cbr>\n14311 W. Warren Ave.\u003Cbr>\nDearborn, MI 48126-1458\u003Cbr>\nSaadTrading@hotmail.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Khalil Saad\n\nRecipient Title\n\nPresident\n\nSaad Trading Inc.\n\n16322 W Warren Ave\n\nDetroit, MI 48228-3703\n\nUnited States\n\nIssuing Office:\n\nDivision of Northern Border Imports\n\nUnited States\n\nDate: January 11, 2022\n\nWARNING LETTER\n\nRe: CMS # 614485\n\nDear Mr. Khalil Saad:\n\nFrom August 18 to September 21, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of Saad Trading Inc. located at 14311 W. Warren Ave., Dearborn MI 48126-1458. We also conducted an inspection on March 4, 17, 24 and 30, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nOur March 2021 inspection was initiated as a result of an FDA sample finding of Salmonella in a plain halva product imported from your foreign supplier, (b)(4). In response to the FDA sample finding, we acknowledge that you voluntarily destroyed all the plain halva product in this shipment. Further on March 4, 2021, this product and foreign manufacturer combination was placed on the Red List of Import Alert 99-19 “Detention Without Physical Examination of Food Products Due to the Presence of Salmonella.” At the conclusion of our inspection, an FDA-483a was issued and we acknowledge receipt of your response dated April 14, 2021 containing various food safety documents from your foreign suppliers.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the following foods you import: plain halva from (b)(4), tahina from (b)(4), and dried okra from (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. To date we have not received a response to the issued FDA 483a.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You must promptly investigate to determine whether your FSVP is adequate and, when appropriate, modify your FSVP when you became aware that a foreign supplier of food that you import does not produce food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, or produces food that is adulterated under section 402 or misbranded under section 403(w) (if applicable), as required by 21 CFR 1.508(b). Further, you must document any investigations, corrective actions, and changes to your FSVP that you undertake. Your firm failed to document any review and assessment of your foreign supplier’s food safety plan after a sample of plain halva product you imported from your approved foreign supplier, (b)(4) tested positive for Salmonella. In addition, you did not modify your FSVP or document any changes you made to your FSVP as appropriate, after you determined that your foreign supplier was not in compliance with the applicable food safety requirements as a result of the positive sample.\n\nIn your FDA Form 483a response dated April 18, 2021, you stated that you “contacted the supplier and notify them with this issue and ask them to re-evaluate the whole process specially the hazard process and what the correction steps will be taken to prevent any issue in the future. . ..” However, we were unable to verify this investigation or any corrective actions during our most recent follow-up inspection because you did not provide FDA with documentation of any action you have taken as a result of the positive sample, such as your documented review and assessment of a recent audit report that includes a review of your foreign supplier’s environmental monitoring program.\n\n2. You must conduct a hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504(a). Although you may meet this requirement by reviewing and assessing the hazard analysis conducted by another entity using a qualified individual, you must document your review and assessment of that hazard analysis, including documenting that the hazard analysis was conducted by a qualified individual (21 CFR 1.504(d)). During our inspection, you provided a hazard analysis from your foreign suppliers for the tahina from your foreign supplier (b)(4) and for the halva from your foreign supplier (b)(4). However, you did not provide documentation that you have reviewed and assessed your foreign supplier’s hazard analyses or that this review and assessment was conducted by a qualified individual.\n\n3. You must approve your foreign suppliers on the basis of an evaluation of your foreign supplier’s performance and the risk posed by the food, in accordance with 21 CFR 1.505(a) for products you import. Moreover, your evaluation must consider applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, as required by 21 CFR 1.505(a)(1)(iii)(B) and you must document this evaluation in accordance with 21 CFR 1.505(a)(2). You did not document any evaluation of the performance of your foreign suppliers, (b)(4); and (b)(4) or your consideration of these suppliers’ compliance with the applicable FDA food safety regulations.\n\n4. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506. Specifically, you did not establish written procedures for ensuring that appropriate supplier verification activities are conducted in accordance with 21 CFR 1.506(b) and you did not document your determination of the appropriate supplier verification activity in accordance with 21 CFR 1.506(d) for the tahini imported from (b)(4); the plain halva imported from (b)(4) and the okra imported from (b)(4).\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your revised FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Mark Kaspar, Compliance Officer, DNBI, USFDA, 550 W Jackson, 15th Floor Chicago IL 60661. If you have any questions regarding this letter, you may contact Mark Kaspar via email at mark.kaspar@fda.hhs.gov. Please reference CMS # 614485 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nKeith J. Jasukaitis\n\nProgram Division Director\n\nDivision of Northern Border Imports\n\ncc:\n\nMr. Khalil Saad, President\n\nSaad Trading, Inc.\n\n14311 W. Warren Ave.\n\nDearborn, MI 48126-1458\n\nSaadTrading@hotmail.com","Saad Trading Inc.","saad-trading-inc-614485-01112022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaad-trading-inc-614485-01112022","2026-10-26T08:09:52.228766+00:00","2022-01-18","614485","Mr. Khalil Saad","2026-08-20T02:16:12.492+00:00","2022-01-11",{"id":299,"raw":300,"subject":39,"body_html":302,"body_text":303,"firm_name":304,"letter_id":305,"created_at":44,"fei_number":19,"letter_url":306,"updated_at":307,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":308,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":309,"body_fetched_at":310,"delivery_method":52,"recipient_title":19,"reference_number":311,"action_taken_date":47,"medical_device_id":19,"response_letter_date":19},3101,[35,36,301,38,39,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsabor-vapors-llc-618564-10072021\">Sabor Vapors LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2100258\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Amelia L. Rivera\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sabor Vapors LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>41 South Fourth Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hamburg\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19526\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:arivera@saborvapors.com\"> arivera@saborvapors.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mrs. Rivera:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Sabor Vapors LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. &nbsp;See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.&nbsp;\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: SABOR VAPORS BUBBLE GUM 60ML 6MG, SABOR VAPORS POMBERRY 60ML 6MG, and SABOR VAPORS ROAR 60ML 6MG.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. &nbsp;These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). &nbsp;In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 27,400 products listed with FDA. FDA received your Premarket Tobacco Product Applications (PMTAs), assigned STNs PM0003536, PM0002115, and PM0004577 on September 8, 2020, September 9, 2020, and on March 10, 2021. &nbsp;However, FDA issued a negative action for STN PM0003536 in the form of a Marketing Denial Order determination on September 01, 2021, which covers 8,219 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003536 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.&nbsp;\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. &nbsp;You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. &nbsp;If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100258, in your response and direct your response to the following address:&nbsp;\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2100258\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nAmelia L. Rivera\n\nRecipient Title\n\nOwner\n\nSabor Vapors LLC\n\n41 South Fourth Street\n\nHamburg, PA 19526\n\nUnited States\n\narivera@saborvapors.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDear Mrs. Rivera:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Sabor Vapors LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: SABOR VAPORS BUBBLE GUM 60ML 6MG, SABOR VAPORS POMBERRY 60ML 6MG, and SABOR VAPORS ROAR 60ML 6MG.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 27,400 products listed with FDA. FDA received your Premarket Tobacco Product Applications (PMTAs), assigned STNs PM0003536, PM0002115, and PM0004577 on September 8, 2020, September 9, 2020, and on March 10, 2021. However, FDA issued a negative action for STN PM0003536 in the form of a Marketing Denial Order determination on September 01, 2021, which covers 8,219 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003536 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100258, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Sabor Vapors LLC","sabor-vapors-llc-618564-10072021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsabor-vapors-llc-618564-10072021","2026-10-26T08:09:52.289598+00:00","618564","Amelia L. Rivera","2026-08-20T02:34:01.354+00:00","ER2100258",{"id":313,"raw":314,"subject":190,"body_html":319,"body_text":320,"firm_name":321,"letter_id":322,"created_at":44,"fei_number":19,"letter_url":323,"updated_at":324,"action_type":22,"case_status":23,"posted_date":325,"marcs_cms_no":326,"product_type":146,"closeout_date":19,"issuing_office":318,"recipient_name":327,"body_fetched_at":328,"delivery_method":329,"recipient_title":19,"reference_number":19,"action_taken_date":330,"medical_device_id":19,"response_letter_date":19},3160,[315,316,317,318,190,13,13,13],"\u003Ctime datetime=\"2021-09-07T13:20:00Z\">09\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-16T04:00:00Z\">08\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fakshar-sales-llc-615274-08162021\">Akshar Sales LLC\u003C\u002Fa>","Division of West Coast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Gautam T. Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FSole Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Akshar Sales LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4807 Davenport Place\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fremont\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94538\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 16, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS #615274\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Patel:\u003C\u002Fp>\n\n\u003Cp>On April 22, 2021 through April 28, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Akshar Sales, LLC, located at 4807 Davenport Place, Fremont, CA 94538. We also conducted an inspection from September 7, 2018 through September 13, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002FFood\u002FGuidanceRegulation\u002FFSMA\u002Fucm361902.htm\">https:\u002F\u002Fwww.fda.gov\u002FFood\u002FGuidanceRegulation\u002FFSMA\u002Fucm361902.htm\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for foods you import including, but not limited to, Chai Biscuits and Fruit Biscuits imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Vermicelli imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the FSVP inspection on April 28, 2021, our investigator provided you with Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We have not received your response to the Form FDA 483a.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You must conduct a hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504(a). Although you may meet this requirement by reviewing and assessing the hazard analysis conducted by another entity using a qualified individual, you must document your review and assessment of that hazard analysis, including documenting that the hazard analysis was conducted by a qualified individual (21 CFR 1.504(d)). During our inspection you provided a hazard analysis obtained from your foreign supplier for your Chai Biscuits and Fruit Biscuits imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Vermicelli imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, for each of these products, you did not provide documentation that you have reviewed and assessed your foreign supplier’s hazard analysis as required by 21 CFR 1.504(d).\u003C\u002Fp>\n\n\u003Cp>2. You did not approve your foreign suppliers on the basis of an evaluation of the foreign supplier’s performance and the risk posed by the food, conducted in accordance with 21 CFR 1.505(a), and document your approval, as required by 21 CFR 1.505(b). Specifically, for your foreign suppliers, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not document your evaluation of the foreign supplier’s performance in accordance with 21 CFR 1.505(a)(2) or your approval of these suppliers in accordance with 21 CFR 1.505(b).\u003C\u002Fp>\n\n\u003Cp>3. You did not establish and follow written procedures to ensure that you import foods only from approved foreign suppliers you have approved based on an evaluation of the foreign supplier’s performance and the risk posed by the food, conducted in accordance with 21 CFR 1.505, and document your use of these procedures, as required by 21 CFR 1.506(a)(1). Specifically, you have not established written procedures for approving foreign suppliers for any of your imported foods.\u003C\u002Fp>\n\n\u003Cp>4. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506 for the products you import. Specifically, you did not document your determination or performance of appropriate supplier verification activities for the Chai Biscuits and Fruit Biscuits imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Vermicelli imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not establish written procedures for ensuring that appropriate supplier verification activities are conducted in accordance with 21 CFR 1.506(b), you did not document your determination of the appropriate supplier verification activity in accordance with 21 CFR 1.506(d), and you did not document (or obtain documentation of) performance of one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing the food and periodically thereafter, as required by 21 CFR 1.506(e).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your revised FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Dennis N. Hoang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Compliance Officer Hoang via email at dennis.hoang@fda.hhs.gov. Please reference CMS # 615274 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Kathleen Turner, DVM\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003Cbr>\nOne World Trade Center, Suite 300\u003Cbr>\nLong Beach, CA 90831\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Gautam T. Patel\n\nRecipient Title\n\nPresident\u002FSole Owner\n\nAkshar Sales LLC\n\n4807 Davenport Place\n\nFremont, CA 94538\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nAugust 16, 2021\n\nWARNING LETTER\n\nRe: CMS #615274\n\nDear Mr. Patel:\n\nOn April 22, 2021 through April 28, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Akshar Sales, LLC, located at 4807 Davenport Place, Fremont, CA 94538. We also conducted an inspection from September 7, 2018 through September 13, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002FFood\u002FGuidanceRegulation\u002FFSMA\u002Fucm361902.htm\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for foods you import including, but not limited to, Chai Biscuits and Fruit Biscuits imported from (b)(4), and (b)(4) Vermicelli imported from (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the FSVP inspection on April 28, 2021, our investigator provided you with Form FDA 483a, FSVP Observations.\n\nWe have not received your response to the Form FDA 483a.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You must conduct a hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504(a). Although you may meet this requirement by reviewing and assessing the hazard analysis conducted by another entity using a qualified individual, you must document your review and assessment of that hazard analysis, including documenting that the hazard analysis was conducted by a qualified individual (21 CFR 1.504(d)). During our inspection you provided a hazard analysis obtained from your foreign supplier for your Chai Biscuits and Fruit Biscuits imported from (b)(4), and (b)(4) Vermicelli imported from (b)(4). However, for each of these products, you did not provide documentation that you have reviewed and assessed your foreign supplier’s hazard analysis as required by 21 CFR 1.504(d).\n\n2. You did not approve your foreign suppliers on the basis of an evaluation of the foreign supplier’s performance and the risk posed by the food, conducted in accordance with 21 CFR 1.505(a), and document your approval, as required by 21 CFR 1.505(b). Specifically, for your foreign suppliers, (b)(4) and (b)(4), you did not document your evaluation of the foreign supplier’s performance in accordance with 21 CFR 1.505(a)(2) or your approval of these suppliers in accordance with 21 CFR 1.505(b).\n\n3. You did not establish and follow written procedures to ensure that you import foods only from approved foreign suppliers you have approved based on an evaluation of the foreign supplier’s performance and the risk posed by the food, conducted in accordance with 21 CFR 1.505, and document your use of these procedures, as required by 21 CFR 1.506(a)(1). Specifically, you have not established written procedures for approving foreign suppliers for any of your imported foods.\n\n4. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506 for the products you import. Specifically, you did not document your determination or performance of appropriate supplier verification activities for the Chai Biscuits and Fruit Biscuits imported from (b)(4), and (b)(4) Vermicelli imported from (b)(4). You did not establish written procedures for ensuring that appropriate supplier verification activities are conducted in accordance with 21 CFR 1.506(b), you did not document your determination of the appropriate supplier verification activity in accordance with 21 CFR 1.506(d), and you did not document (or obtain documentation of) performance of one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing the food and periodically thereafter, as required by 21 CFR 1.506(e).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your revised FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Dennis N. Hoang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Compliance Officer Hoang via email at dennis.hoang@fda.hhs.gov. Please reference CMS # 615274 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nKathleen Turner, DVM\n\nProgram Division Director\n\nDivision of West Coast Imports\n\nOne World Trade Center, Suite 300\n\nLong Beach, CA 90831","Akshar Sales LLC","akshar-sales-llc-615274-08162021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fakshar-sales-llc-615274-08162021","2026-10-26T08:07:51.914142+00:00","2021-09-07","615274","Mr. Gautam T. Patel","2026-08-20T02:37:09.274+00:00","United Parcel Service","2021-08-16",{"id":332,"raw":333,"subject":338,"body_html":339,"body_text":340,"firm_name":341,"letter_id":342,"created_at":343,"fei_number":19,"letter_url":344,"updated_at":345,"action_type":22,"case_status":23,"posted_date":346,"marcs_cms_no":347,"product_type":348,"closeout_date":19,"issuing_office":337,"recipient_name":349,"body_fetched_at":350,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":351,"medical_device_id":19,"response_letter_date":19},21666,[334,335,336,337,338,13,13,13],"\u003Ctime datetime=\"2026-10-13T04:00:00Z\">10\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-05T04:00:00Z\">08\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flewis-sausage-company-inc-717432-08052026\">Lewis Sausage Company Inc. \u003C\u002Fa>","Center for Veterinary Medicine","CGMP\u002FFood for Animals\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Donald Myers\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u002FOwner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lewis Sausage Company Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1050 Old Savannah Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Burgaw\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>28225-0280\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dmyers@lewissausage.com\"> dmyers@lewissausage.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 717432\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 5, 2026\u003C\u002Fp>\u003Cp>Dear Donald Myers:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) and North Carolina Department of Agriculture and Consumer Services (NCDACS) conducted a joint inspection of your pet food manufacturing facility, located at 1050 Old Savannah Road, Burgaw, North Carolina, from August 25 through August 29, 2025, as a follow-up to an Untitled Letter issued to your facility on March 14, 2025. We also received and evaluated your written responses to the Form FDA 483, Inspectional Observations (FDA 483), dated September 22, 2025, and March 19, 2026.\u003C\u002Fp>\u003Cp>During the inspection, the investigators found evidence of significant violations of FDA’s Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements, Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507), which cause your products to be adulterated in that they were prepared, packed, or held under insanitary conditions whereby they may have been contaminated with filth, or whereby they may have been rendered injurious to health.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Also, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive control requirements of 21 CFR Part 507 (located in subparts A, C, D, E, and F of Part 507) is a prohibited act.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>On August 11, 2025, NCDACS, in cooperation with FDA, conducted sampling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Chicken Dog Food, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Pet Food Mixer, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4) \u003C\u002Fstrong>Turkey &amp; Beef Puppy Food, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which you contract manufacture. The unopened samples were collected from a third-party wholesale distributor. Sample analysis revealed the finished products contained \u003Cem>Salmonella\u003C\u002Fem> or \u003Cem>Listeria monocytogenes\u003C\u002Fem>, as described below. Therefore, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Chicken Dog Food, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Chicken Pet Food Mixer, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Turkey &amp; Beef Puppy Food, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are adulterated in that they bear or contain a poisonous or deleterious substance which may render them injurious to health.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> These pathogen-positive samples led to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>This letter notifies you of the violations of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) that we found during our inspection of your operation. You may find the FD&amp;C Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>At the close of the inspection, you were issued an FDA 483. As noted above, we received your response dated September 22, 2025, and March 19, 2026. We have reviewed your response, and we discuss your proposed corrections below in relation to each of the noted violations.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls Requirements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your animal food facility is subject to the Hazard Analysis and Risk-Based Preventive Controls requirements found in 21 CFR part 507, subparts A, C, D, E, and F. During our inspection of your facility, the investigators observed evidence of significant violations of these requirements, including the following:\u003C\u002Fp>\u003Cp>1. You did not identify and implement preventive controls to provide assurances that any hazards requiring a preventive control are significantly minimized or prevented and the animal food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the FD&amp;C Act, as required by 21 CFR 507.34(a)(1).\u003C\u002Fp>\u003Cp>Your hazard analysis, titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” dated July 28, 2025, identified biological hazards including \u003Cem>Salmonella\u003C\u002Fem>, \u003Cem>L. monocytogenes\u003C\u002Fem>, and \u003Cem>Escherichia coli\u003C\u002Fem> O157:H7 as hazards requiring a preventive control at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” manufacturing step. Your food safety plan identified one process preventive control which includes applying \u003Cstrong>(b)(4)\u003C\u002Fstrong> to control pathogen hazards. However, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> preventive controls are not adequate, as shown by the following samples\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of three finished products that were collected after implementation of your preventive control and found to contain \u003Cem>Salmonella\u003C\u002Fem> or \u003Cem>L. monocytogenes\u003C\u002Fem>:\u003C\u002Fp>\u003Cul>\u003Cli>Sample \u003Cstrong>(b)(4)\u003C\u002Fstrong> Chicken Pet Food Mixer, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was found to contain \u003Cem>Salmonella Enteritidis\u003C\u002Fem>.\u003C\u002Fli>\u003Cli>Sample \u003Cstrong>(b)(4)\u003C\u002Fstrong> Chicken Dog Food, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was found to contain \u003Cem>Salmonella Enteritidis\u003C\u002Fem>.\u003C\u002Fli>\u003Cli>Sample \u003Cstrong>(b)(4)\u003C\u002Fstrong> Turkey &amp; Beef Puppy Food, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was found to contain \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Additionally, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” SOP (SOP-507.34-01) states to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” You verbally stated during the inspection, the mixing time was \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is not established in your written procedure. However, our investigators observed mixing times of 153, 142, and 75 seconds on August 27, 2025, during the production of turkey food for cats, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>Your response dated September 22, 2025, included a corrective and preventive action report for the lots of pet food referenced above, an updated hazard analysis that includes an updated preventive control for pathogens, a new monitoring record for the updated preventive control, an updated \u003Cstrong>(b)(4)\u003C\u002Fstrong> Procedure, and an assessment of mixing times on \u003Cstrong>(b)(4)\u003C\u002Fstrong> distribution. However, your March 19, 2026, response indicates you have replaced \u003Cstrong>(b)(4)\u003C\u002Fstrong> in-process ingredients with \u003Cstrong>(b)(4)\u003C\u002Fstrong> of finished products in final packaging as a preventive control for biological hazards.\u003C\u002Fp>\u003Cp>In your March 19, 2026, response, you also presented an updated food safety plan, “Finished Product Pathogen Testing Program” (SOP-507.49.01), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your finished products. Your updated hazard analysis identifies that \u003Cstrong>(b)(4)\u003C\u002Fstrong> addresses biological hazards associated with your ingredients and process, and that you have contracted a third-party manufacturing facility to conduct the \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing on finished products. However, we are unable to fully evaluate the adequacy of your corrective actions because you did not provide documentation supporting that this preventive control has been implemented for the finished products you manufacture.\u003C\u002Fp>\u003Cp>2. You did not validate that the preventive controls you identified and implemented in accordance with 21 CFR 507.34 are adequate to control the hazard as appropriate to the nature of the preventive control and its role in your facility’s food safety system, as required by 21 CFR 507.47(a).\u003C\u002Fp>\u003Cp>Specifically, your firm added \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a preventive control for pathogens in your pet food products in accordance with the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” SOP (SOP-507.34-01). You implemented this procedure based upon \u003Cstrong>(b)(4)\u003C\u002Fstrong> studies conducted by your third-party consulting laboratory regarding the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your pet food products. FDA’s review of your validation studies using \u003Cstrong>(b)(4)\u003C\u002Fstrong> to control \u003Cem>Salmonella\u003C\u002Fem> and \u003Cem>L. monocytogenes\u003C\u002Fem> determined these studies do not support your claim that the probiotic is an effective preventive control. This is further demonstrated by the detection of \u003Cem>Salmonella\u003C\u002Fem> or \u003Cem>L. monocytogenes\u003C\u002Fem> in your finished pet food as described above.\u003C\u002Fp>\u003Cp>Additionally, your validation studies did not address other pathogens you have determined to be hazards requiring a preventive control, such as \u003Cem>E. coli\u003C\u002Fem> O157:H7.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>In your written response, dated September 22, 2025, you provided \u003Cstrong>(b)(4)\u003C\u002Fstrong> studies previously submitted to the FDA as well as supplemental information pertaining to the studies. However, your March 19, 2026, response indicated you have replaced the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of in-process ingredients with \u003Cstrong>(b)(4)\u003C\u002Fstrong> of finished products in final packaging as a preventive control.\u003C\u002Fp>\u003Cp>Additionally, in your written response, dated March 19, 2026, you presented \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation studies for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You evaluated the inactivation of \u003Cem>Salmonella, L. monocytogenes\u003C\u002Fem>, and Shiga toxin-producing \u003Cem>Escherichia coli\u003C\u002Fem> using continuous \u003Cstrong>(b)(4)\u003C\u002Fstrong> of pathogens. We have reviewed your validations and note the validation studies do not include determination of the pathogenic load for your product before undergoing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Without knowing the typical starting pathogenic load for your product, we are unable to determine if the \u003Cstrong>(b)(4)\u003C\u002Fstrong> achieved by your \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation studies is adequate to significantly minimize\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> pathogens. We acknowledge that in Table \u003Cstrong>(b)(4)\u003C\u002Fstrong> of each study, you analyzed \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, \u003Cstrong>(b)(4)\u003C\u002Fstrong> is an indicator of the overall microbial population and does not directly measure the presence\u002Fabsence of pathogenic microorganisms.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Conclusion\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to regulatory action, or where appropriate, legal action.\u003C\u002Fp>\u003Cp>For more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\u003C\u002Fp>\u003Cul>\u003Cli>For Industry | FDA (https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fresources-you\u002Findustry)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe your products are not in violation of the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>The Food &amp; Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of any response you choose to submit to this letter. We encourage you to submit files up to 100 megabytes in a single email, and to divide files greater than 100 megabytes so they may be submitted as smaller files in separate emails. If you submit electronic correspondence, please ensure that your facility’s name, the CMS number at the top of this letter, and the inspection location are included in your correspondence. We intend to issue an electronic acknowledgement upon receipt of your email.\u003C\u002Fp>\u003Cp>Please direct your electronic correspondence to Compliance Officer Andrew J. Howard at Andrew.Howard@fda.hhs.gov. If you have questions regarding this letter, please contact Compliance Officer Andrew J. Howard by telephone at (410) 779-5125, or by email.\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Isaac K. Carney\u003Cbr>Director of Food Compliance, Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>Cc:\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>\u003Cbr>North Carolina Department of Agriculture and Consumer Services\u003Cbr>4400 Reedy Creek Road\u003Cbr>Raleigh, NC 27607\u003Cbr>\u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 342(a)(4)], and 21 CFR 507.1(a)(1)(ii).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(uu) of the FD&amp;C Act [21 U.S.C. § 331(uu)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See Section 402(a)(1) of the FD&amp;C Act [21 U.S.C. § 342(a)(1)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Although NCDACS collected these samples, FDA reviewed and concurred with the NCDACS sample collection and analytical report packages.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Significantly minimize means to reduce to an acceptable level, including to eliminate (21 CFR 507.3).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nDonald Myers\n\nRecipient Title\n\nGeneral Manager\u002FOwner\n\nLewis Sausage Company Inc.\n\n1050 Old Savannah Road\n\nBurgaw, NC 28225-0280\n\nUnited States\n\ndmyers@lewissausage.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nCMS # 717432\nAugust 5, 2026\nDear Donald Myers:\nThe U.S. Food and Drug Administration (FDA) and North Carolina Department of Agriculture and Consumer Services (NCDACS) conducted a joint inspection of your pet food manufacturing facility, located at 1050 Old Savannah Road, Burgaw, North Carolina, from August 25 through August 29, 2025, as a follow-up to an Untitled Letter issued to your facility on March 14, 2025. We also received and evaluated your written responses to the Form FDA 483, Inspectional Observations (FDA 483), dated September 22, 2025, and March 19, 2026.\nDuring the inspection, the investigators found evidence of significant violations of FDA’s Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements, Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507), which cause your products to be adulterated in that they were prepared, packed, or held under insanitary conditions whereby they may have been contaminated with filth, or whereby they may have been rendered injurious to health.1 The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.2 Also, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive control requirements of 21 CFR Part 507 (located in subparts A, C, D, E, and F of Part 507) is a prohibited act.3\nOn August 11, 2025, NCDACS, in cooperation with FDA, conducted sampling of (b)(4) Chicken Dog Food, lot (b)(4), (b)(4) Pet Food Mixer, lot (b)(4), and (b)(4) Turkey & Beef Puppy Food, lot (b)(4), which you contract manufacture. The unopened samples were collected from a third-party wholesale distributor. Sample analysis revealed the finished products contained Salmonella or Listeria monocytogenes, as described below. Therefore, your (b)(4) Chicken Dog Food, lot (b)(4), (b)(4) Chicken Pet Food Mixer, lot (b)(4), and (b)(4) Turkey & Beef Puppy Food, lot (b)(4), are adulterated in that they bear or contain a poisonous or deleterious substance which may render them injurious to health.4 These pathogen-positive samples led to (b)(4).\nThis letter notifies you of the violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) that we found during our inspection of your operation. You may find the FD&C Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\nAt the close of the inspection, you were issued an FDA 483. As noted above, we received your response dated September 22, 2025, and March 19, 2026. We have reviewed your response, and we discuss your proposed corrections below in relation to each of the noted violations.\nHazard Analysis and Risk-Based Preventive Controls Requirements\nYour animal food facility is subject to the Hazard Analysis and Risk-Based Preventive Controls requirements found in 21 CFR part 507, subparts A, C, D, E, and F. During our inspection of your facility, the investigators observed evidence of significant violations of these requirements, including the following:\n1. You did not identify and implement preventive controls to provide assurances that any hazards requiring a preventive control are significantly minimized or prevented and the animal food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the FD&C Act, as required by 21 CFR 507.34(a)(1).\nYour hazard analysis, titled “(b)(4),” dated July 28, 2025, identified biological hazards including Salmonella, L. monocytogenes, and Escherichia coli O157:H7 as hazards requiring a preventive control at the “(b)(4)” manufacturing step. Your food safety plan identified one process preventive control which includes applying (b)(4) to control pathogen hazards. However, your (b)(4) preventive controls are not adequate, as shown by the following samples5 of three finished products that were collected after implementation of your preventive control and found to contain Salmonella or L. monocytogenes:\nSample (b)(4) Chicken Pet Food Mixer, lot (b)(4), was found to contain Salmonella Enteritidis.\nSample (b)(4) Chicken Dog Food, lot (b)(4), was found to contain Salmonella Enteritidis.\nSample (b)(4) Turkey & Beef Puppy Food, lot (b)(4), was found to contain L. monocytogenes.\nAdditionally, your “(b)(4)” SOP (SOP-507.34-01) states to (b)(4).” You verbally stated during the inspection, the mixing time was (b)(4), which is not established in your written procedure. However, our investigators observed mixing times of 153, 142, and 75 seconds on August 27, 2025, during the production of turkey food for cats, lot (b)(4).\nEvaluation of your response:\nYour response dated September 22, 2025, included a corrective and preventive action report for the lots of pet food referenced above, an updated hazard analysis that includes an updated preventive control for pathogens, a new monitoring record for the updated preventive control, an updated (b)(4) Procedure, and an assessment of mixing times on (b)(4) distribution. However, your March 19, 2026, response indicates you have replaced (b)(4) in-process ingredients with (b)(4) of finished products in final packaging as a preventive control for biological hazards.\nIn your March 19, 2026, response, you also presented an updated food safety plan, “Finished Product Pathogen Testing Program” (SOP-507.49.01), and (b)(4) studies (b)(4) of your finished products. Your updated hazard analysis identifies that (b)(4) addresses biological hazards associated with your ingredients and process, and that you have contracted a third-party manufacturing facility to conduct the (b)(4) processing on finished products. However, we are unable to fully evaluate the adequacy of your corrective actions because you did not provide documentation supporting that this preventive control has been implemented for the finished products you manufacture.\n2. You did not validate that the preventive controls you identified and implemented in accordance with 21 CFR 507.34 are adequate to control the hazard as appropriate to the nature of the preventive control and its role in your facility’s food safety system, as required by 21 CFR 507.47(a).\nSpecifically, your firm added (b)(4) as a preventive control for pathogens in your pet food products in accordance with the “(b)(4)” SOP (SOP-507.34-01). You implemented this procedure based upon (b)(4) studies conducted by your third-party consulting laboratory regarding the use of (b)(4) in your pet food products. FDA’s review of your validation studies using (b)(4) to control Salmonella and L. monocytogenes determined these studies do not support your claim that the probiotic is an effective preventive control. This is further demonstrated by the detection of Salmonella or L. monocytogenes in your finished pet food as described above.\nAdditionally, your validation studies did not address other pathogens you have determined to be hazards requiring a preventive control, such as E. coli O157:H7.\nEvaluation of your response:\nIn your written response, dated September 22, 2025, you provided (b)(4) studies previously submitted to the FDA as well as supplemental information pertaining to the studies. However, your March 19, 2026, response indicated you have replaced the (b)(4) of in-process ingredients with (b)(4) of finished products in final packaging as a preventive control.\nAdditionally, in your written response, dated March 19, 2026, you presented (b)(4) validation studies for (b)(4). You evaluated the inactivation of Salmonella, L. monocytogenes, and Shiga toxin-producing Escherichia coli using continuous (b)(4) of pathogens. We have reviewed your validations and note the validation studies do not include determination of the pathogenic load for your product before undergoing (b)(4). Without knowing the typical starting pathogenic load for your product, we are unable to determine if the (b)(4) achieved by your (b)(4) validation studies is adequate to significantly minimize6 pathogens. We acknowledge that in Table (b)(4) of each study, you analyzed (b)(4) and (b)(4). However, (b)(4) is an indicator of the overall microbial population and does not directly measure the presence\u002Fabsence of pathogenic microorganisms.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to regulatory action, or where appropriate, legal action.\nFor more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\nFor Industry | FDA (https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fresources-you\u002Findustry)\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe your products are not in violation of the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\nThe Food & Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of any response you choose to submit to this letter. We encourage you to submit files up to 100 megabytes in a single email, and to divide files greater than 100 megabytes so they may be submitted as smaller files in separate emails. If you submit electronic correspondence, please ensure that your facility’s name, the CMS number at the top of this letter, and the inspection location are included in your correspondence. We intend to issue an electronic acknowledgement upon receipt of your email.\nPlease direct your electronic correspondence to Compliance Officer Andrew J. Howard at Andrew.Howard@fda.hhs.gov. If you have questions regarding this letter, please contact Compliance Officer Andrew J. Howard by telephone at (410) 779-5125, or by email.\n\u002FS\u002F\nIsaac K. Carney\nDirector of Food Compliance, Office of Surveillance and Compliance\nCenter for Veterinary Medicine\nU.S. Food and Drug Administration\nCc:\n(b)(4)\n(b)(6), (b)(7)(C)\nNorth Carolina Department of Agriculture and Consumer Services\n4400 Reedy Creek Road\nRaleigh, NC 27607\n(b)(6), (b)(7)(C)\n_____________________________\n1 See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(4)], and 21 CFR 507.1(a)(1)(ii).\n2 See Section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n3 See Section 301(uu) of the FD&C Act [21 U.S.C. § 331(uu)].\n4 See Section 402(a)(1) of the FD&C Act [21 U.S.C. § 342(a)(1)].\n5 Although NCDACS collected these samples, FDA reviewed and concurred with the NCDACS sample collection and analytical report packages.\n6 Significantly minimize means to reduce to an acceptable level, including to eliminate (21 CFR 507.3).","Lewis Sausage Company Inc.","lewis-sausage-company-inc-717432-08052026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flewis-sausage-company-inc-717432-08052026","2026-11-17T01:02:03.701861+00:00","2026-10-13","717432","Animal & Veterinary","Donald Myers","2026-10-14T12:31:58.108+00:00","2026-08-05",{"id":353,"raw":354,"subject":212,"body_html":358,"body_text":359,"firm_name":360,"letter_id":361,"created_at":123,"fei_number":19,"letter_url":362,"updated_at":363,"action_type":22,"case_status":23,"posted_date":364,"marcs_cms_no":365,"product_type":26,"closeout_date":19,"issuing_office":251,"recipient_name":366,"body_fetched_at":367,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":368,"medical_device_id":19,"response_letter_date":19},1600,[355,356,357,251,210,13,13,13],"\u003Ctime datetime=\"2024-02-20T14:20:00Z\">02\u002F20\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-13T05:00:00Z\">02\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsalvacion-usa-inc-672252-02132024\">Salvacion USA Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ryan S. Hwang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Salvacion USA Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>210 Sylvan Avenue Suite 24\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Englewood Cliffs\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07632-2503\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@cofixyl.com\"> info@cofixyl.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Hello@Covixyl.com\"> Hello@Covixyl.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 13, 2024\u003Cbr>\n\u003Cbr>\nRE: 3017660889\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hwang:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of the drug product Covixyl Nasal Spray.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fcovixyl.com\u002F on October 10, 2023. On the same date, we also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002Fgocovixyl and https:\u002F\u002Fwww.facebook.com\u002Fcovixyl, directing consumers to your website https:\u002F\u002Fcovixyl.com\u002F to purchase your products. Based on our review, Covixyl Nasal Spray is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Covixyl Nasal Spray is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your website https:\u002F\u002Fcovixyl.com\u002F, and your social media websites https:\u002F\u002Ftwitter.com\u002Fgocovixyl and https:\u002F\u002Fwww.facebook.com\u002Fcovixyl, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; “Covixyl® was developed to safely and effectively create a barrier in the nasal passages that helps block airborne viruses, keeping you from getting sick.” [from your website https:\u002F\u002Fcovixyl.com\u002F]\u003Cbr>\n\u003Cbr>\n&nbsp; &nbsp; &nbsp; “Initial testing against \u003Cstrong>SARS-CoV-2, Rotavirus, H1N1 (Influenza A), and Human Respiratory Syncytial Virus (RSV)\u003C\u002Fstrong> proved the efficacy of ELAH against infection in vitro, showing 99+% reduction across all 4 viruses.” [from your website https:\u002F\u002Fcovixyl.com\u002F]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; “Laboratory testing and clinical trials have proven the power of Covixyl® to block airborne viruses before they gain entry into the body, for up to 6 hours.” [from your website https:\u002F\u002Fcovixyl.com\u002F]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; “Covixyl® creates a physical barrier in the nasopharynx which prevents airborne respiratory viruses from attaching to the cell walls, protecting the body from infection for up to six hours per use.” [from your website https:\u002F\u002Fcovixyl.com\u002F]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; “Protection that Lasts up to 6 Hours” [from your website https:\u002F\u002Fcovixyl.com\u002F]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; “The Future of Virus Protection is Here” [from your website https:\u002F\u002Fcovixyl.com\u002F]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; “Covixyl is the future of virus protection and your partner in crime to a healthy, care-free life...&nbsp;\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Drug-free\u003C\u002Fli>\n\t\u003Cli>Non-addictive\u003C\u002Fli>\n\t\u003Cli>6 hours of protection\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; Choose Covixyl and claim your life back!” [from a September 28, 2023 post on your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Fcovixyl]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; “…Here's to all the teachers who are on the frontlines with sneezing and sniffling kiddos You are the real MVPs\u003Cbr>\n&nbsp; &nbsp; &nbsp; Looking for a better way to stay protected from viruses in the classroom? Covixyl blocks airborne viruses, giving you an extra layer of protection!” [from an October 5, 2023 post on your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Fcovixyl]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; “…Covixyl is the virus-blocking nasal spray that allows you to live life safely, easily, and freely!” covixyl.com\u002F#order-now” [from an August 3, 2023 post on your X (formerly Twitter) webpage at https:\u002F\u002Ftwitter.com\u002Fgocovixyl]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; “Allow me to (re) introduce myself, my name is CO… We are Covixyl, a nasal spray that blocks airborne viruses before they attack! Spray, Protect, Reconnect and Shop now at Covixyly.com #Tripledemic #flu” [from an October 26, 2022 post on your X (formerly Twitter) webpage at https:\u002F\u002Ftwitter.com\u002Fgocovixyl]\u003C\u002Fp>\n\n\u003Cp>Your Covixyl Nasal Spray product is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for Covixyl Nasal Spray. Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent by email to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance at FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nOffice Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your firm markets this product to contain Ethyl Lauroyl Arginate HCl (ELAH).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRyan S. Hwang\n\nRecipient Title\n\nDirector\n\nSalvacion USA Inc.\n\n210 Sylvan Avenue Suite 24\n\nEnglewood Cliffs, NJ 07632-2503\n\nUnited States\n\ninfo@cofixyl.com\n\nHello@Covixyl.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nFebruary 13, 2024\n\nRE: 3017660889\n\nDear Mr. Hwang:\n\nThis letter concerns your firm’s distribution of the drug product Covixyl Nasal Spray.1 The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fcovixyl.com\u002F on October 10, 2023. On the same date, we also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002Fgocovixyl and https:\u002F\u002Fwww.facebook.com\u002Fcovixyl, directing consumers to your website https:\u002F\u002Fcovixyl.com\u002F to purchase your products. Based on our review, Covixyl Nasal Spray is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). These violations are described in more detail below.\n\nUnapproved New Drug Violations\n\nYour Covixyl Nasal Spray is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\n\nExamples of claims from your website https:\u002F\u002Fcovixyl.com\u002F, and your social media websites https:\u002F\u002Ftwitter.com\u002Fgocovixyl and https:\u002F\u002Fwww.facebook.com\u002Fcovixyl, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\n\n“Covixyl® was developed to safely and effectively create a barrier in the nasal passages that helps block airborne viruses, keeping you from getting sick.” [from your website https:\u002F\u002Fcovixyl.com\u002F]\n\n“Initial testing against SARS-CoV-2, Rotavirus, H1N1 (Influenza A), and Human Respiratory Syncytial Virus (RSV) proved the efficacy of ELAH against infection in vitro, showing 99+% reduction across all 4 viruses.” [from your website https:\u002F\u002Fcovixyl.com\u002F]\n\n“Laboratory testing and clinical trials have proven the power of Covixyl® to block airborne viruses before they gain entry into the body, for up to 6 hours.” [from your website https:\u002F\u002Fcovixyl.com\u002F]\n\n“Covixyl® creates a physical barrier in the nasopharynx which prevents airborne respiratory viruses from attaching to the cell walls, protecting the body from infection for up to six hours per use.” [from your website https:\u002F\u002Fcovixyl.com\u002F]\n\n“Protection that Lasts up to 6 Hours” [from your website https:\u002F\u002Fcovixyl.com\u002F]\n\n“The Future of Virus Protection is Here” [from your website https:\u002F\u002Fcovixyl.com\u002F]\n\n“Covixyl is the future of virus protection and your partner in crime to a healthy, care-free life...\n\nDrug-free\n\nNon-addictive\n\n6 hours of protection\n\nChoose Covixyl and claim your life back!” [from a September 28, 2023 post on your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Fcovixyl]\n\n“…Here's to all the teachers who are on the frontlines with sneezing and sniffling kiddos You are the real MVPs\n\nLooking for a better way to stay protected from viruses in the classroom? Covixyl blocks airborne viruses, giving you an extra layer of protection!” [from an October 5, 2023 post on your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Fcovixyl]\n\n“…Covixyl is the virus-blocking nasal spray that allows you to live life safely, easily, and freely!” covixyl.com\u002F#order-now” [from an August 3, 2023 post on your X (formerly Twitter) webpage at https:\u002F\u002Ftwitter.com\u002Fgocovixyl]\n\n“Allow me to (re) introduce myself, my name is CO… We are Covixyl, a nasal spray that blocks airborne viruses before they attack! Spray, Protect, Reconnect and Shop now at Covixyly.com #Tripledemic #flu” [from an October 26, 2022 post on your X (formerly Twitter) webpage at https:\u002F\u002Ftwitter.com\u002Fgocovixyl]\n\nYour Covixyl Nasal Spray product is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for Covixyl Nasal Spray. Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent by email to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance at FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nOffice Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n______________________\n\n1 Your firm markets this product to contain Ethyl Lauroyl Arginate HCl (ELAH).","Salvacion USA Inc.","salvacion-usa-inc-672252-02132024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsalvacion-usa-inc-672252-02132024","2026-10-26T08:09:53.087022+00:00","2024-02-20","672252","Ryan S. Hwang","2026-08-20T00:17:42.324+00:00","2024-02-13",{"id":370,"raw":371,"subject":252,"body_html":375,"body_text":376,"firm_name":377,"letter_id":378,"created_at":123,"fei_number":19,"letter_url":379,"updated_at":380,"action_type":22,"case_status":23,"posted_date":381,"marcs_cms_no":382,"product_type":26,"closeout_date":19,"issuing_office":251,"recipient_name":383,"body_fetched_at":384,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":385,"medical_device_id":19,"response_letter_date":19},1640,[372,373,374,251,252,13,13,13],"\u003Ctime datetime=\"2024-01-30T14:20:00Z\">01\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-24T05:00:00Z\">01\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsambrosa-care-inc-673321-01242024\">Sambrosa Care Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John F.R. de Wit, Pharm.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Sambrosa Care Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9171 Wilshire Boulevard Suite 500\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beverly Hills\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90210\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:john@dromenwinkel.com\"> john@dromenwinkel.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:john@sambrosacare.com\"> john@sambrosacare.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 24, 2024\u003C\u002Fp>\n\n\u003Cp>Re: FEI #3018095920\u003C\u002Fp>\n\n\u003Cp>Dear Dr. de Wit:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of the over-the-counter (OTC) combination antihistamine and nighttime sleep-aid drug product “Sambrosa sweet dreams Night Syrup.” “Sambrosa sweet dreams Night Syrup” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and is also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Sambrosa sweet dreams Night Syrup” is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a combination antihistamine and nighttime sleep-aid drug product.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims from the products’ labeling, including your firm’s product website https:\u002F\u002Fwww.sambrosa.com\u002F where the product is available for purchase, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Uses\u003C\u002Fstrong> temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: ■ sneezing ■ runny nose ■ itchy, watery eyes ■ itching of the nose or throat” [from your product label]\u003C\u002Fp>\n\n\u003Cp>“Looking for the best OTC sleeping syrup? Sambrosa Sweet Dreams is specially formulated to promote a good night’s rest. It combines the naturally-based ingredients of honey and 7 organic herbs with a small dose of doxylamine, which will help achieve both nighttime allergy relief and the quality rest you need...” [from your product website at https:\u002F\u002Fwww.sambrosa.com\u002Fproduct\u002Fsambrosa-300-ml\u002F]\u003C\u002Fp>\n\n\u003Cp>“Our Ingredients…Honey is quite amazing in its taste and in its countless health benefits; it is an antibacterial, anti-inflammatory, and contains antioxidants…California poppy extract is considered to be a nervine, which means that it may work to maintain a normal nervous system function, and it’s often used as a sedative to induce sleep…Hawthorn species are shrubs or small trees. Hawthorn was already a staple in herbal medicine, said to strengthen cardiovascular function and stimulate blood circulation…Hops adds a bitter flavor and is a stability agent. In herbal medicine this plant is known to benefit conditions such as anxiety and insomnia, and it contains phyto-estrogen which can relieve the symptoms of menopause… Mistletoe is famous for adding a romantic touch to Christmas, but there’s much more to it than just that—it’s used in herbal medicine for headaches, dizziness, energy loss, irritability and exhaustion…Passion Flower Is a climbing vine with beautiful flowers, and is recommended as a sedative and antispasmodic agent. It’s used for anxiety, insomnia and restlessness…Oats are very nutritious—they are a great source of dietary fiber, minerals, important vitamins and antioxidants. In herbal medicine, oats extract is used for anxiety and stress, and for its antimicrobial effects and sedative, soothing effects…White Chestnut is used as a reliever of repetitive thoughts and worrying.” [from your product website at https:\u002F\u002Fwww.sambrosa.com\u002Fshop\u002F]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, “Sambrosa sweet dreams Night Syrup” is intended for use as a combination antihistamine and nighttime sleep-aid drug product. As described below, your drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless it is lawfully marketed under section 505G of the FD&amp;C Act. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for your drug product identified above.\u003C\u002Fp>\n\n\u003Cp>Your “Sambrosa sweet dreams Night Syrup” is subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to OTC antihistamine drug products, such products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use (hereafter M012).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, your “Sambrosa sweet dreams Night Syrup” does not conform to conditions specified in M012.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Specifically, your product contains 9.78 mg of doxylamine succinate per each 3 mL dose. The product's directions for use for “adults and children 6 years of age and over,” which read “take 3 mL every 4 to 6 hours. Do not exceed 35 mL in 24 hours.\" may result in a daily dose of 114.1 mg of doxylamine succinate, which is 76.6 mg of doxylamine succinate more than the daily maximum dose of 37.5 mg that is allowed for children between 6 and 12 years of age and 39.1 mg above the 75 mg daily maximum dose that is allowed for adults and children above 12 years of age under M012.72(d)(8). For your information, M012.72(d)(8) states “Adults and children 12 years of age and over: oral dosage is 7.5 to 12.5 milligrams every 4 to 6 hours, not to exceed 75 milligrams in 24 hours, or as directed by a doctor. Children 6 to under 12 years of age: oral dosage is 3.75 to 6.25 milligrams every 4 to 6 hours, not to exceed 37.5 milligrams in 24 hours, or as directed by a doctor.”\u003C\u002Fp>\n\n\u003Cp>Additionally, your product is labeled to contain the combination of active ingredients that include honey, California poppy, hawthorn, hops, mistletoe, passion flower, oats, and white chestnut. However, none of these ingredients in combination or as sole ingredients are acceptable or recognized as an active ingredient in M012. Although the immediate product label does not specifically list these ingredients as active ingredients, the claims on the product website as listed above, demonstrate that they are each an “active ingredient” as defined in 21 CFR 201.66(b)(2) because they are intended to furnish pharmacological activity.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Furthermore, these intended use claims go beyond the general intended uses and do not comply with the applicable final order.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Therefore, your “Sambrosa sweet dreams Night Syrup” drug product does not comply with the cold, cough monograph described above, and it is not otherwise marketed in accordance with section 505G. Thus, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Sambrosa sweet dreams Night Syrup” is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nOffice Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003Cbr>\n\u003Cbr>\ncc:\u003C\u002Fp>\n\n\u003Cp>Bart Quik, Pharm.D.\u003Cbr>\nManaging Director\u003Cbr>\nLelypharma BV\u003Cbr>\nZuiveringweg 42\u003Cbr>\nLelystad 8243PZ Netherlands (NLD)\u003Cbr>\nbartquik@lelypharma.nl\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 C.F.R. part 330, prior to enactment of the CARES Act. In the case of OTC antihistamine drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter (OTC) Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000026, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that your “Sambrosa sweet dreams Night Syrup” also appears to be indicated for use as a nighttime sleep aid. OTC nighttime sleep aid drug products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M010: Nighttime Sleep Aid Drug Products for Over the Counter Human Use (M010). Your product does not conform to the conditions set forth in this monograph because, among other things, “Sambrosa sweet dreams Night Syrup” is formulated with the active ingredient, doxylamine succinate, which is not permitted under M010 for use as a nighttime sleep-aid. Furthermore, neither M012 nor M010 include provisions allowing for a combination antihistamine and nighttime sleep-aid product.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Sambrosa sweet dreams Night Syrup” is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJohn F.R. de Wit, Pharm.D.\n\nSambrosa Care Inc.\n\n9171 Wilshire Boulevard Suite 500\n\nBeverly Hills, CA 90210\n\nUnited States\n\njohn@dromenwinkel.com\n\njohn@sambrosacare.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nJanuary 24, 2024\n\nRe: FEI #3018095920\n\nDear Dr. de Wit:\n\nThis letter concerns your firm’s distribution of the over-the-counter (OTC) combination antihistamine and nighttime sleep-aid drug product “Sambrosa sweet dreams Night Syrup.” “Sambrosa sweet dreams Night Syrup” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and is also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranding Violations\n\n“Sambrosa sweet dreams Night Syrup” is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a combination antihistamine and nighttime sleep-aid drug product.\n\nExamples of the claims from the products’ labeling, including your firm’s product website https:\u002F\u002Fwww.sambrosa.com\u002F where the product is available for purchase, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but are not limited to, the following:\n\n“Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: ■ sneezing ■ runny nose ■ itchy, watery eyes ■ itching of the nose or throat” [from your product label]\n\n“Looking for the best OTC sleeping syrup? Sambrosa Sweet Dreams is specially formulated to promote a good night’s rest. It combines the naturally-based ingredients of honey and 7 organic herbs with a small dose of doxylamine, which will help achieve both nighttime allergy relief and the quality rest you need...” [from your product website at https:\u002F\u002Fwww.sambrosa.com\u002Fproduct\u002Fsambrosa-300-ml\u002F]\n\n“Our Ingredients…Honey is quite amazing in its taste and in its countless health benefits; it is an antibacterial, anti-inflammatory, and contains antioxidants…California poppy extract is considered to be a nervine, which means that it may work to maintain a normal nervous system function, and it’s often used as a sedative to induce sleep…Hawthorn species are shrubs or small trees. Hawthorn was already a staple in herbal medicine, said to strengthen cardiovascular function and stimulate blood circulation…Hops adds a bitter flavor and is a stability agent. In herbal medicine this plant is known to benefit conditions such as anxiety and insomnia, and it contains phyto-estrogen which can relieve the symptoms of menopause… Mistletoe is famous for adding a romantic touch to Christmas, but there’s much more to it than just that—it’s used in herbal medicine for headaches, dizziness, energy loss, irritability and exhaustion…Passion Flower Is a climbing vine with beautiful flowers, and is recommended as a sedative and antispasmodic agent. It’s used for anxiety, insomnia and restlessness…Oats are very nutritious—they are a great source of dietary fiber, minerals, important vitamins and antioxidants. In herbal medicine, oats extract is used for anxiety and stress, and for its antimicrobial effects and sedative, soothing effects…White Chestnut is used as a reliever of repetitive thoughts and worrying.” [from your product website at https:\u002F\u002Fwww.sambrosa.com\u002Fshop\u002F]\n\nUnapproved New Drug Violations\n\nBased on the above labeling claims, “Sambrosa sweet dreams Night Syrup” is intended for use as a combination antihistamine and nighttime sleep-aid drug product. As described below, your drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless it is lawfully marketed under section 505G of the FD&C Act. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for your drug product identified above.\n\nYour “Sambrosa sweet dreams Night Syrup” is subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to OTC antihistamine drug products, such products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use (hereafter M012).1 However, your “Sambrosa sweet dreams Night Syrup” does not conform to conditions specified in M012.2\n\nSpecifically, your product contains 9.78 mg of doxylamine succinate per each 3 mL dose. The product's directions for use for “adults and children 6 years of age and over,” which read “take 3 mL every 4 to 6 hours. Do not exceed 35 mL in 24 hours.\" may result in a daily dose of 114.1 mg of doxylamine succinate, which is 76.6 mg of doxylamine succinate more than the daily maximum dose of 37.5 mg that is allowed for children between 6 and 12 years of age and 39.1 mg above the 75 mg daily maximum dose that is allowed for adults and children above 12 years of age under M012.72(d)(8). For your information, M012.72(d)(8) states “Adults and children 12 years of age and over: oral dosage is 7.5 to 12.5 milligrams every 4 to 6 hours, not to exceed 75 milligrams in 24 hours, or as directed by a doctor. Children 6 to under 12 years of age: oral dosage is 3.75 to 6.25 milligrams every 4 to 6 hours, not to exceed 37.5 milligrams in 24 hours, or as directed by a doctor.”\n\nAdditionally, your product is labeled to contain the combination of active ingredients that include honey, California poppy, hawthorn, hops, mistletoe, passion flower, oats, and white chestnut. However, none of these ingredients in combination or as sole ingredients are acceptable or recognized as an active ingredient in M012. Although the immediate product label does not specifically list these ingredients as active ingredients, the claims on the product website as listed above, demonstrate that they are each an “active ingredient” as defined in 21 CFR 201.66(b)(2) because they are intended to furnish pharmacological activity.3 Furthermore, these intended use claims go beyond the general intended uses and do not comply with the applicable final order.4\n\nTherefore, your “Sambrosa sweet dreams Night Syrup” drug product does not comply with the cold, cough monograph described above, and it is not otherwise marketed in accordance with section 505G. Thus, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMisbranding Violations\n\n“Sambrosa sweet dreams Night Syrup” is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nOffice Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\ncc:\n\nBart Quik, Pharm.D.\n\nManaging Director\n\nLelypharma BV\n\nZuiveringweg 42\n\nLelystad 8243PZ Netherlands (NLD)\n\nbartquik@lelypharma.nl\n\n(b)(4)\n\n______________________\n\n1 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 C.F.R. part 330, prior to enactment of the CARES Act. In the case of OTC antihistamine drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter (OTC) Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000026, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.)\n\n2 We note that your “Sambrosa sweet dreams Night Syrup” also appears to be indicated for use as a nighttime sleep aid. OTC nighttime sleep aid drug products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M010: Nighttime Sleep Aid Drug Products for Over the Counter Human Use (M010). Your product does not conform to the conditions set forth in this monograph because, among other things, “Sambrosa sweet dreams Night Syrup” is formulated with the active ingredient, doxylamine succinate, which is not permitted under M010 for use as a nighttime sleep-aid. Furthermore, neither M012 nor M010 include provisions allowing for a combination antihistamine and nighttime sleep-aid product.\n\n3 Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\n4 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Sambrosa sweet dreams Night Syrup” is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.","Sambrosa Care Inc.","sambrosa-care-inc-673321-01242024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsambrosa-care-inc-673321-01242024","2026-10-26T08:09:53.118589+00:00","2024-01-30","673321","John F.R. de Wit, Pharm.D.","2026-08-20T00:21:46.331+00:00","2024-01-24",96,{"510k":388,"classification":389,"enforcement":390,"event":391,"event_backfill":392,"pma":393,"warning_letter":394},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]